PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32786316-2	2020	Pramipexole is classified as a non-ergoline aminobenzothiazole compound that selectively agonizes the dopamine D2-like receptor subfamily, which includes the D2, D3, and D4 receptor subtypes.	Pramipexole	0-11	dopamine receptor D4	Homo sapiens	170-181
33111449-11	2021	Thus, the treatment with pramipexole in the evaluated dose and time tended to alter the expression of the PTPRD protein in the spinal cord, in addition to significantly improving the sleep pattern.	Pramipexole	25-36	protein tyrosine phosphatase, receptor type, D	Rattus norvegicus	106-111
32750392-0	2020	Lack of correlation between dyskinesia and pallidal serotonin transporter expression-induced by L-Dopa and Pramipexole in hemiparkinsonian rats.	Pramipexole	107-118	solute carrier family 6 member 4	Rattus norvegicus	52-73
32750392-8	2020	The number of GP SERT-positive axon varicosities was increased in L-Dopa (p < 0.05) and Pramipexole (p < 0.01) treated rats.	Pramipexole	88-99	solute carrier family 6 member 4	Rattus norvegicus	17-21
32819568-0	2020	Dopamine receptor D3 agonist (Pramipexole) reduces morphine-induced cardiac fibrosis.	Pramipexole	30-41	dopamine receptor D3	Mus musculus	0-20
32540990-0	2020	Nrf2/HO-1 mediates neuroprotective effects of pramipexole by attenuating oxidative damage and mitochondrial perturbation after traumatic brain injury.	Pramipexole	46-57	NFE2 like bZIP transcription factor 2	Rattus norvegicus	0-4
32540990-0	2020	Nrf2/HO-1 mediates neuroprotective effects of pramipexole by attenuating oxidative damage and mitochondrial perturbation after traumatic brain injury.	Pramipexole	46-57	heme oxygenase 1	Rattus norvegicus	5-9
32540990-13	2020	Further, PPX treatment reduced the Bax/Bcl2 ratio and translocation of Bax to mitochondria and cytochrome-c to cytosol.	Pramipexole	9-12	BCL2 associated X, apoptosis regulator	Rattus norvegicus	35-38
32540990-13	2020	Further, PPX treatment reduced the Bax/Bcl2 ratio and translocation of Bax to mitochondria and cytochrome-c to cytosol.	Pramipexole	9-12	BCL2, apoptosis regulator	Rattus norvegicus	39-43
32540990-13	2020	Further, PPX treatment reduced the Bax/Bcl2 ratio and translocation of Bax to mitochondria and cytochrome-c to cytosol.	Pramipexole	9-12	BCL2 associated X, apoptosis regulator	Rattus norvegicus	71-74
32540990-14	2020	Finally, PPX treatment greatly accelerated the translocation of Nrf2 to the nucleus and upregulated the HO-1 protein expression.	Pramipexole	9-12	NFE2 like bZIP transcription factor 2	Rattus norvegicus	64-68
32540990-14	2020	Finally, PPX treatment greatly accelerated the translocation of Nrf2 to the nucleus and upregulated the HO-1 protein expression.	Pramipexole	9-12	heme oxygenase 1	Rattus norvegicus	104-108
31538542-4	2020	In order to shed light on this issue, DRD2- and DRD3-overexpressing cells and drd2 KO, drd3 KO and wild-type mice were treated with the DRD2-DRD3 agonist pramipexole.	Pramipexole	154-165	dopamine receptor D2	Mus musculus	78-82
31538542-4	2020	In order to shed light on this issue, DRD2- and DRD3-overexpressing cells and drd2 KO, drd3 KO and wild-type mice were treated with the DRD2-DRD3 agonist pramipexole.	Pramipexole	154-165	dopamine receptor D2	Mus musculus	136-140
31538542-4	2020	In order to shed light on this issue, DRD2- and DRD3-overexpressing cells and drd2 KO, drd3 KO and wild-type mice were treated with the DRD2-DRD3 agonist pramipexole.	Pramipexole	154-165	dopamine receptor D3	Mus musculus	141-145
31538542-5	2020	The results revealed that pramipexole induces autophagy through MTOR inhibition and a DRD3-dependent but DRD2-independent mechanism.	Pramipexole	26-37	mechanistic target of rapamycin kinase	Mus musculus	64-68
31538542-5	2020	The results revealed that pramipexole induces autophagy through MTOR inhibition and a DRD3-dependent but DRD2-independent mechanism.	Pramipexole	26-37	dopamine receptor D3	Mus musculus	86-90
31538542-5	2020	The results revealed that pramipexole induces autophagy through MTOR inhibition and a DRD3-dependent but DRD2-independent mechanism.	Pramipexole	26-37	dopamine receptor D2	Mus musculus	105-109
31811458-12	2020	Moreover, addition of miR-494-3p and silence of BDNF mitigated the effect of PPX on MPP+-induced neurotoxicity.	Pramipexole	77-80	brain derived neurotrophic factor	Homo sapiens	48-52
32172399-0	2020	Pramipexole Reduces zif-268 mRNA Expression in Brain Structures involved in the Generation of Harmaline-Induced Tremor.	Pramipexole	0-11	early growth response 1	Rattus norvegicus	20-27
32172399-3	2020	The aim of the present study was to investigate brain targets for the tremorolytic effect of pramipexole by determination of the early activity-dependent gene zif-268 mRNA expression.	Pramipexole	93-104	early growth response 1	Rattus norvegicus	159-166
32172399-9	2020	Pramipexole reversed both the harmaline-induced tremor and the increase in zif-268 mRNA expression in the inferior olive, cerebellar cortex and motor cortex.	Pramipexole	0-11	early growth response 1	Rattus norvegicus	75-82
32735501-0	2020	Efficacy of pramipexole combined with levodopa for Parkinson"s disease treatment and their effects on QOL and serum TNF-alpha levels.	Pramipexole	12-23	tumor necrosis factor	Homo sapiens	116-125
32735501-8	2020	CONCLUSION: Pramipexole combined with levodopa relieved PD symptoms and improved the quality of life of PD patients, potentially by suppressing serum TNF-alpha levels.	Pramipexole	12-23	tumor necrosis factor	Homo sapiens	150-159
32546033-13	2021	miR-19b was found higher in ropinirole drug used group than that of pramipexole group.Conclusion: This study suggests that serum miR-29c expression level might be potential biomarker in the diagnosis of Turkish Parkinson patients.	Pramipexole	68-79	microRNA 29c	Homo sapiens	129-136
31811458-13	2020	PPX inhibited MPP+-induced neurotoxicity in SK-N-SH and CHP 212 cells by decreasing miR-494-3p and increasing BDNF, indicating the potential therapeutic effect of PPX on Parkinson"s disease.	Pramipexole	0-3	brain derived neurotrophic factor	Homo sapiens	110-114
31811458-0	2020	Pramipexole Inhibits MPP+-Induced Neurotoxicity by miR-494-3p/BDNF.	Pramipexole	0-11	brain derived neurotrophic factor	Homo sapiens	62-66
31811458-13	2020	PPX inhibited MPP+-induced neurotoxicity in SK-N-SH and CHP 212 cells by decreasing miR-494-3p and increasing BDNF, indicating the potential therapeutic effect of PPX on Parkinson"s disease.	Pramipexole	163-166	brain derived neurotrophic factor	Homo sapiens	110-114
31235613-1	2019	A dopamine D2 receptor agonist, pramipexole, has been found to elicit neuroprotection in patients with Parkinson"s disease and restless leg syndrome.	Pramipexole	32-43	dopamine receptor D2	Homo sapiens	2-22
31085186-8	2019	Moreover, both rotigotine and pramipexole shortened the duration of freezing in the fear conditioning test, but only in the mSPS-exposed mice.	Pramipexole	30-41	spontaneous seizure	Mus musculus	124-128
30291939-5	2018	We report that DEX improved LTP maintenance in CA1 neurons of acute hippocampal slices from aged but not young rats.	Pramipexole	15-18	carbonic anhydrase 1	Rattus norvegicus	47-50
31324936-2	2019	OBJECTIVES: This study used computational modelling to characterise the reinforcement learning processes underlying patterns of PRL behaviour observed in SUD and OCD and to show how the dopamine D2/3 receptor agonist pramipexole and the D2/3 antagonist amisulpride affected these responses.	Pramipexole	217-228	dopamine receptor D2	Homo sapiens	186-208
30423289-5	2019	The interaction was also increased by pramipexole, a D2R agonist commonly used in the treatment of PD, indicating a possible clinically relevance.	Pramipexole	38-49	dopamine receptor D2	Mus musculus	53-56
31008016-2	2019	Pramipexole is a small molecule used in the treatment of idiopathic and uremic RLS.	Pramipexole	0-11	RLS1	Homo sapiens	79-82
31008016-6	2019	MATERIALS AND METHODS: Our patient was a 63-year-old man on chronic HD for 5 years who had been treated uneventfully with oral pramipexole for uremic RLS since then.	Pramipexole	127-138	RLS1	Homo sapiens	150-153
30033298-1	2018	In this present paper, a simple voltammetric method has been reported for the simultaneous determination of acetaminophen (AC), pramipexole (PRX) and carbamazepine (CBZ) using ZSM-5 nanozeolite-TiO2 nanoparticles composite modified carbon paste electrode (ZSM-5/TiO2/CPE).	Pramipexole	141-144	carboxypeptidase E	Homo sapiens	267-270
30033298-4	2018	The oxidation peak currents of AC, PRX and CBZ at the surface of ZSM-5/TiO2/CPE were increased dramatically against CPE and their overpotentials decreased.	Pramipexole	35-38	carboxypeptidase E	Homo sapiens	76-79
29953413-0	2018	CircSNCA downregulation by pramipexole treatment mediates cell apoptosis and autophagy in Parkinson"s disease by targeting miR-7.	Pramipexole	27-38	leukocyte immunoglobulin like receptor B1	Homo sapiens	123-128
30033298-4	2018	The oxidation peak currents of AC, PRX and CBZ at the surface of ZSM-5/TiO2/CPE were increased dramatically against CPE and their overpotentials decreased.	Pramipexole	35-38	carboxypeptidase E	Homo sapiens	116-119
28695622-0	2018	Sleep disturbance by pramipexole is modified by Meis1 in mice.	Pramipexole	21-32	Meis homeobox 1	Mus musculus	48-53
28695622-4	2018	We report a detailed sleep analysis of heterozygous Meis1 knockout mice and challenge it with pramipexole, a dopamine agonist used in the treatment of RLS.	Pramipexole	94-105	Meis homeobox 1	Mus musculus	52-57
29481916-0	2018	Pramipexole and Fingolimod exert neuroprotection in a mouse model of Parkinson"s disease by activation of sphingosine kinase 1 and Akt kinase.	Pramipexole	0-11	sphingosine kinase 1	Mus musculus	106-126
29390063-6	2018	Pretreatment with pramipexole (PPX), a preferential D3R agonist, showed antidepressant effects on LPS-induced depression-like behavior through preventing changes in LPS-induced proinflammatory cytokines (tumour necrosis factor-alpha, interleukin-1beta, and interleukin-6), BDNF, and ERK1/2-CREB signaling pathway in the VTA and NAc.	Pramipexole	18-29	dopamine receptor D3	Mus musculus	52-55
29390063-6	2018	Pretreatment with pramipexole (PPX), a preferential D3R agonist, showed antidepressant effects on LPS-induced depression-like behavior through preventing changes in LPS-induced proinflammatory cytokines (tumour necrosis factor-alpha, interleukin-1beta, and interleukin-6), BDNF, and ERK1/2-CREB signaling pathway in the VTA and NAc.	Pramipexole	18-29	interleukin 1 beta	Mus musculus	234-251
29390063-6	2018	Pretreatment with pramipexole (PPX), a preferential D3R agonist, showed antidepressant effects on LPS-induced depression-like behavior through preventing changes in LPS-induced proinflammatory cytokines (tumour necrosis factor-alpha, interleukin-1beta, and interleukin-6), BDNF, and ERK1/2-CREB signaling pathway in the VTA and NAc.	Pramipexole	18-29	interleukin 6	Mus musculus	257-270
29390063-6	2018	Pretreatment with pramipexole (PPX), a preferential D3R agonist, showed antidepressant effects on LPS-induced depression-like behavior through preventing changes in LPS-induced proinflammatory cytokines (tumour necrosis factor-alpha, interleukin-1beta, and interleukin-6), BDNF, and ERK1/2-CREB signaling pathway in the VTA and NAc.	Pramipexole	18-29	brain derived neurotrophic factor	Mus musculus	273-277
29390063-6	2018	Pretreatment with pramipexole (PPX), a preferential D3R agonist, showed antidepressant effects on LPS-induced depression-like behavior through preventing changes in LPS-induced proinflammatory cytokines (tumour necrosis factor-alpha, interleukin-1beta, and interleukin-6), BDNF, and ERK1/2-CREB signaling pathway in the VTA and NAc.	Pramipexole	18-29	mitogen-activated protein kinase 3	Mus musculus	283-289
29390063-6	2018	Pretreatment with pramipexole (PPX), a preferential D3R agonist, showed antidepressant effects on LPS-induced depression-like behavior through preventing changes in LPS-induced proinflammatory cytokines (tumour necrosis factor-alpha, interleukin-1beta, and interleukin-6), BDNF, and ERK1/2-CREB signaling pathway in the VTA and NAc.	Pramipexole	18-29	cAMP responsive element binding protein 1	Mus musculus	290-294
29390063-6	2018	Pretreatment with pramipexole (PPX), a preferential D3R agonist, showed antidepressant effects on LPS-induced depression-like behavior through preventing changes in LPS-induced proinflammatory cytokines (tumour necrosis factor-alpha, interleukin-1beta, and interleukin-6), BDNF, and ERK1/2-CREB signaling pathway in the VTA and NAc.	Pramipexole	31-34	dopamine receptor D3	Mus musculus	52-55
29390063-6	2018	Pretreatment with pramipexole (PPX), a preferential D3R agonist, showed antidepressant effects on LPS-induced depression-like behavior through preventing changes in LPS-induced proinflammatory cytokines (tumour necrosis factor-alpha, interleukin-1beta, and interleukin-6), BDNF, and ERK1/2-CREB signaling pathway in the VTA and NAc.	Pramipexole	31-34	interleukin 1 beta	Mus musculus	234-251
29390063-6	2018	Pretreatment with pramipexole (PPX), a preferential D3R agonist, showed antidepressant effects on LPS-induced depression-like behavior through preventing changes in LPS-induced proinflammatory cytokines (tumour necrosis factor-alpha, interleukin-1beta, and interleukin-6), BDNF, and ERK1/2-CREB signaling pathway in the VTA and NAc.	Pramipexole	31-34	interleukin 6	Mus musculus	257-270
29390063-6	2018	Pretreatment with pramipexole (PPX), a preferential D3R agonist, showed antidepressant effects on LPS-induced depression-like behavior through preventing changes in LPS-induced proinflammatory cytokines (tumour necrosis factor-alpha, interleukin-1beta, and interleukin-6), BDNF, and ERK1/2-CREB signaling pathway in the VTA and NAc.	Pramipexole	31-34	brain derived neurotrophic factor	Mus musculus	273-277
29390063-6	2018	Pretreatment with pramipexole (PPX), a preferential D3R agonist, showed antidepressant effects on LPS-induced depression-like behavior through preventing changes in LPS-induced proinflammatory cytokines (tumour necrosis factor-alpha, interleukin-1beta, and interleukin-6), BDNF, and ERK1/2-CREB signaling pathway in the VTA and NAc.	Pramipexole	31-34	mitogen-activated protein kinase 3	Mus musculus	283-289
29390063-6	2018	Pretreatment with pramipexole (PPX), a preferential D3R agonist, showed antidepressant effects on LPS-induced depression-like behavior through preventing changes in LPS-induced proinflammatory cytokines (tumour necrosis factor-alpha, interleukin-1beta, and interleukin-6), BDNF, and ERK1/2-CREB signaling pathway in the VTA and NAc.	Pramipexole	31-34	cAMP responsive element binding protein 1	Mus musculus	290-294
29056363-0	2018	Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington"s disease.	Pramipexole	0-11	huntingtin	Mus musculus	35-45
29361389-8	2018	The post-hoc analyses including the time of evolution and Pramipexol or Ropinirole treatments, confirmed the independent effect of the DRD3 upon ICDs (p = .028) and ICDARs (p = .041) as well as the interaction between DRD3 and Pramipexol treatment upon ICDARs (OR = 4.60, 95% CI 1.20-17.632, p = .026).	Pramipexole	58-68	dopamine receptor D3	Homo sapiens	135-139
29361389-8	2018	The post-hoc analyses including the time of evolution and Pramipexol or Ropinirole treatments, confirmed the independent effect of the DRD3 upon ICDs (p = .028) and ICDARs (p = .041) as well as the interaction between DRD3 and Pramipexol treatment upon ICDARs (OR = 4.60, 95% CI 1.20-17.632, p = .026).	Pramipexole	227-237	dopamine receptor D3	Homo sapiens	135-139
29531524-0	2018	Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling.	Pramipexole	15-26	brain derived neurotrophic factor	Homo sapiens	104-108
29531524-0	2018	Ropinirole and Pramipexole Promote Structural Plasticity in Human iPSC-Derived Dopaminergic Neurons via BDNF and mTOR Signaling.	Pramipexole	15-26	mechanistic target of rapamycin kinase	Homo sapiens	113-117
29531524-5	2018	Ropinirole and pramipexole produced dose-dependent increases of dendritic arborization and soma size after 3 days of culture, effects antagonized by the selective D3R antagonists SB277011-A and S33084 and by the mTOR pathway kinase inhibitors LY294002 and rapamycin.	Pramipexole	15-26	mechanistic target of rapamycin kinase	Homo sapiens	212-216
29056363-9	2018	Pramipexole reduced striatal levels of soluble mHTT and increased the size of intranuclear inclusions in R6/1 mice.	Pramipexole	0-11	huntingtin	Mus musculus	47-51
28631520-0	2017	Striatal changes underlie MPEP-mediated suppression of the acquisition and expression of pramipexole-induced place preference in an alpha-synuclein rat model of Parkinson"s disease.	Pramipexole	89-100	synuclein alpha	Rattus norvegicus	132-147
28631520-3	2017	We previously demonstrated that the rewarding effect of the D2/D3 agonist pramipexole was enhanced after repeated exposure to L-dopa and alpha-synuclein mediated dopaminergic nigral loss with specific transcriptional signatures suggesting a key involvement of the glutamatergic pathway.	Pramipexole	74-85	synuclein alpha	Rattus norvegicus	137-152
27817855-8	2017	Our results suggest that genotype in DRD3 Ser9Gly was the main factor determining different doses of DAs and PD patients carrying Gly/Gly genotype require higher doses of pramipexole for effective treatment.	Pramipexole	171-182	dopamine receptor D3	Homo sapiens	37-41
26801190-0	2017	Pramipexole, a Dopamine D2/D3 Receptor-Preferring Agonist, Prevents Experimental Autoimmune Encephalomyelitis Development in Mice.	Pramipexole	0-11	dopamine receptor D2	Mus musculus	24-38
26801190-3	2017	Herein, we hypothesized that pramipexole (PPX), a dopamine D2/D3 receptor-preferring agonist commonly used to treat Parkinson"s disease (PD), would be a suitable therapeutic drug for EAE.	Pramipexole	29-40	dopamine receptor D2	Mus musculus	59-73
26801190-3	2017	Herein, we hypothesized that pramipexole (PPX), a dopamine D2/D3 receptor-preferring agonist commonly used to treat Parkinson"s disease (PD), would be a suitable therapeutic drug for EAE.	Pramipexole	42-45	dopamine receptor D2	Mus musculus	59-73
26801190-8	2017	Moreover, PPX inhibited the production of inflammatory cytokines, such as IL-17, IL-1beta, and TNF-alpha in peripheral lymphoid tissue.	Pramipexole	10-13	interleukin 1 beta	Mus musculus	81-89
26801190-8	2017	Moreover, PPX inhibited the production of inflammatory cytokines, such as IL-17, IL-1beta, and TNF-alpha in peripheral lymphoid tissue.	Pramipexole	10-13	tumor necrosis factor	Mus musculus	95-104
28845959-11	2017	The main pharmacologic options for RLS management are dopaminergic agonists (eg, pramipexole and ropinirole); gabapentinoids also are good options.	Pramipexole	81-92	RLS1	Homo sapiens	35-38
28818004-4	2017	Augmentation, which refers to a paradoxical treatment-related increase in RLS symptoms, has been associated with all three dopamine agonists approved for the treatment of RLS - rotigotine, pramipexole, and ropinirole.	Pramipexole	189-200	RLS1	Homo sapiens	74-77
28415529-5	2017	It was found that the TMDS-MWCNT/GCE exhibits good catalytic activity toward oxidation of pramipexole (PPX) drug, leading to a concentration range of 0.8 to 600muM with a detection limit of 0.2muM at 3sigma using the differential pulse voltammetry technique, a sensitivity of 0.084muAmuM-1, and a correlation coefficient of 0.991.	Pramipexole	90-101	aminomethyltransferase	Homo sapiens	22-36
28415529-5	2017	It was found that the TMDS-MWCNT/GCE exhibits good catalytic activity toward oxidation of pramipexole (PPX) drug, leading to a concentration range of 0.8 to 600muM with a detection limit of 0.2muM at 3sigma using the differential pulse voltammetry technique, a sensitivity of 0.084muAmuM-1, and a correlation coefficient of 0.991.	Pramipexole	103-106	aminomethyltransferase	Homo sapiens	22-36
27958259-1	2017	Acute hyperkinesia after discontinuation of tramadol in a patient with chronic pain using citalopram and pramipexole for restless legs syndrome (RLS) has not been reported.	Pramipexole	105-116	RLS1	Homo sapiens	145-148
27958259-8	2017	Sudden discontinuation of tramadol in a patient under pramipexole for RLS may cause severe, choreatic hyperkinesias for hours, which immediately resolve upon intravenous fentanyl.	Pramipexole	54-65	RLS1	Homo sapiens	70-73
27958259-9	2017	In patients under pramipexole for RLS and tramadol and fentanyl for chronic pain, sudden discontinuation of tramadol should be avoided to prevent induction of restless body syndrome.	Pramipexole	18-29	RLS1	Homo sapiens	34-37
26239766-1	2015	Pramipexole is a D3 dopamine receptor-preferring agonist indicated for the treatment of Parkinson disease.	Pramipexole	0-11	dopamine receptor D3	Homo sapiens	17-37
27562098-4	2016	To improve this picture, since 2009 we introduced the non-ergot dopamine agonist pramipexole as an adjunct to l-dopa therapy in the treatment of the most common causes of BH4 deficiency, 6-pyruvoyl tetrahydropterin synthase (PTPS) deficiency and dihydropteridine reductase (DHPR) deficiency.	Pramipexole	81-92	6-pyruvoyltetrahydropterin synthase	Homo sapiens	187-223
27562098-4	2016	To improve this picture, since 2009 we introduced the non-ergot dopamine agonist pramipexole as an adjunct to l-dopa therapy in the treatment of the most common causes of BH4 deficiency, 6-pyruvoyl tetrahydropterin synthase (PTPS) deficiency and dihydropteridine reductase (DHPR) deficiency.	Pramipexole	81-92	6-pyruvoyltetrahydropterin synthase	Homo sapiens	225-229
27026509-0	2016	Pramipexole-Induced Hypothermia Reduces Early Brain Injury via PI3K/AKT/GSK3beta pathway in Subarachnoid Hemorrhage rats.	Pramipexole	0-11	AKT serine/threonine kinase 1	Rattus norvegicus	68-71
27026509-0	2016	Pramipexole-Induced Hypothermia Reduces Early Brain Injury via PI3K/AKT/GSK3beta pathway in Subarachnoid Hemorrhage rats.	Pramipexole	0-11	glycogen synthase kinase 3 beta	Rattus norvegicus	72-80
27026509-8	2016	Pramipexole-induced hypothermia ameliorated SAH-induced brain cell death, blood-brain barrier damage and neurobehavioral deficits in a PI3K/AKT/GSK3beta signaling-dependent manner.	Pramipexole	0-11	AKT serine/threonine kinase 1	Rattus norvegicus	140-143
27026509-8	2016	Pramipexole-induced hypothermia ameliorated SAH-induced brain cell death, blood-brain barrier damage and neurobehavioral deficits in a PI3K/AKT/GSK3beta signaling-dependent manner.	Pramipexole	0-11	glycogen synthase kinase 3 beta	Rattus norvegicus	144-152
27026509-9	2016	Therefore, we may conclude that pramipexole-induced hypothermia could effectively inhibit EBI after SAH in rats via PI3K/AKT/GSK3beta signaling pathway.	Pramipexole	32-43	AKT serine/threonine kinase 1	Rattus norvegicus	121-124
27026509-9	2016	Therefore, we may conclude that pramipexole-induced hypothermia could effectively inhibit EBI after SAH in rats via PI3K/AKT/GSK3beta signaling pathway.	Pramipexole	32-43	glycogen synthase kinase 3 beta	Rattus norvegicus	125-133
26628402-0	2016	Adaptive down-regulation of the serotonin transporter in the 6-hydroxydopamine-induced rat model of preclinical stages of Parkinson"s disease and after chronic pramipexole treatment.	Pramipexole	160-171	solute carrier family 6 member 4	Rattus norvegicus	32-53
27488420-4	2016	METHODS: Pergolide (0.001-1 muM) and pramipexole (0.01-200 muM) were administered to 8 day primary murine mesencephalic cultures for 24 h. in the presence or absence of desferal, sulpiride or cycloheximide.	Pramipexole	37-48	latexin	Homo sapiens	59-62
27216859-7	2016	However, the pramipexole-induced increase in waiting impulsivity observed in both sham and lesioned rats, was more pronounced in HI lesioned rats, which displayed a restricted alpha-synuclein-induced dopaminergic neurodegeneration.	Pramipexole	13-24	synuclein alpha	Rattus norvegicus	176-191
27588058-0	2016	Effects of pramipexole treatment on the alpha-synuclein content in serum exosomes of Parkinson"s disease patients.	Pramipexole	11-22	synuclein alpha	Homo sapiens	40-55
27588058-14	2016	The therapeutic effect of pramipexole may be associated with its reducing effect on the relative expression of alpha-synuclein in serum exosomes.	Pramipexole	26-37	synuclein alpha	Homo sapiens	111-126
27261607-1	2016	Pramipexole is a dopamine D2 receptor agonist indicated for treating Parkinson disorder.	Pramipexole	0-11	dopamine receptor D2	Mus musculus	17-37
27261607-10	2016	Altogether, our data suggest that the antidepressant-like effect of pramipexole is dependent on the activation of D2 receptor and inhibition of either NMDA receptors and/or NO-cGMP synthesis.	Pramipexole	68-79	dopamine receptor D2	Mus musculus	114-125
25739024-9	2015	Chronic pramipexole increased BDNF mRNA, but decreased trkB mRNA in the VTA in lesioned rats.	Pramipexole	8-19	brain-derived neurotrophic factor	Rattus norvegicus	30-34
26649942-3	2015	In this study, we report that dopamine D2 and D3 receptor (DRD2 and DRD3) activation by pramipexole and quinpirole could enhance BECN1 transcription and promote autophagy activation in several cell lines, including PC12, MES23.5 and differentiated SH-SY5Y cells, and also in tyrosine hydroxylase positive primary midbrain neurons.	Pramipexole	88-99	dopamine receptor D2	Rattus norvegicus	59-63
26649942-3	2015	In this study, we report that dopamine D2 and D3 receptor (DRD2 and DRD3) activation by pramipexole and quinpirole could enhance BECN1 transcription and promote autophagy activation in several cell lines, including PC12, MES23.5 and differentiated SH-SY5Y cells, and also in tyrosine hydroxylase positive primary midbrain neurons.	Pramipexole	88-99	dopamine receptor D3	Rattus norvegicus	68-72
26649942-3	2015	In this study, we report that dopamine D2 and D3 receptor (DRD2 and DRD3) activation by pramipexole and quinpirole could enhance BECN1 transcription and promote autophagy activation in several cell lines, including PC12, MES23.5 and differentiated SH-SY5Y cells, and also in tyrosine hydroxylase positive primary midbrain neurons.	Pramipexole	88-99	beclin 1	Rattus norvegicus	129-134
26649942-6	2015	More importantly, pramipexole treatment ameliorated the SNCA/alpha-synuclein accumulation in rotenone-treated PC12 cells that overexpress wild-type or A53T mutant SNCA by promoting autophagy flux.	Pramipexole	18-29	synuclein alpha	Rattus norvegicus	56-60
26649942-6	2015	More importantly, pramipexole treatment ameliorated the SNCA/alpha-synuclein accumulation in rotenone-treated PC12 cells that overexpress wild-type or A53T mutant SNCA by promoting autophagy flux.	Pramipexole	18-29	synuclein alpha	Rattus norvegicus	61-76
26649942-6	2015	More importantly, pramipexole treatment ameliorated the SNCA/alpha-synuclein accumulation in rotenone-treated PC12 cells that overexpress wild-type or A53T mutant SNCA by promoting autophagy flux.	Pramipexole	18-29	synuclein alpha	Rattus norvegicus	163-167
26649942-8	2015	The inhibition of SNCA accumulation by pramipexole was attenuated by cotreatment with the DRD2 and DRD3 antagonists and Becn1 siRNAs.	Pramipexole	39-50	synuclein alpha	Rattus norvegicus	18-22
26649942-8	2015	The inhibition of SNCA accumulation by pramipexole was attenuated by cotreatment with the DRD2 and DRD3 antagonists and Becn1 siRNAs.	Pramipexole	39-50	dopamine receptor D2	Rattus norvegicus	90-94
26649942-8	2015	The inhibition of SNCA accumulation by pramipexole was attenuated by cotreatment with the DRD2 and DRD3 antagonists and Becn1 siRNAs.	Pramipexole	39-50	dopamine receptor D3	Rattus norvegicus	99-103
26649942-8	2015	The inhibition of SNCA accumulation by pramipexole was attenuated by cotreatment with the DRD2 and DRD3 antagonists and Becn1 siRNAs.	Pramipexole	39-50	beclin 1	Rattus norvegicus	120-125
26112716-11	2015	In vitro, in the cultured PBMC treated with 10 mumol/L pramipexole, the Nurr1 mRNA levels were significantly increased by 99.61%, 71.75%, 73.16% in 2, 4, and 8 h, respectively (P < 0.001).	Pramipexole	55-66	nuclear receptor subfamily 4 group A member 2	Homo sapiens	72-77
26360835-2	2015	Previously the organic cation transporter 2 (OCT2) was shown to be involved in the uptake of pramipexole by renal tubular cells, while the mechanism underlying efflux into tubular lumen remains unclear.	Pramipexole	93-104	solute carrier family 22 member 2	Canis lupus familiaris	15-43
26360835-2	2015	Previously the organic cation transporter 2 (OCT2) was shown to be involved in the uptake of pramipexole by renal tubular cells, while the mechanism underlying efflux into tubular lumen remains unclear.	Pramipexole	93-104	solute carrier family 22 member 2	Canis lupus familiaris	45-49
26360835-3	2015	Cimetidine, a potent inhibitor of multidrug and toxin extrusion proteins 1 (MATE1) and 2-K (MATE2-K), decreases renal pramipexole clearance in humans.	Pramipexole	118-129	solute carrier family 47 member 1	Homo sapiens	76-81
26360835-3	2015	Cimetidine, a potent inhibitor of multidrug and toxin extrusion proteins 1 (MATE1) and 2-K (MATE2-K), decreases renal pramipexole clearance in humans.	Pramipexole	118-129	solute carrier family 47 member 2	Homo sapiens	92-99
26360835-5	2015	Pramipexole uptake was investigated using MDCK or HEK cells overexpressing OCT2, MATE1 or MATE2-K and the respective vector controls (Co).	Pramipexole	0-11	solute carrier family 22 member 2	Canis lupus familiaris	75-79
26360835-5	2015	Pramipexole uptake was investigated using MDCK or HEK cells overexpressing OCT2, MATE1 or MATE2-K and the respective vector controls (Co).	Pramipexole	0-11	solute carrier family 47 member 1	Homo sapiens	81-86
26360835-5	2015	Pramipexole uptake was investigated using MDCK or HEK cells overexpressing OCT2, MATE1 or MATE2-K and the respective vector controls (Co).	Pramipexole	0-11	solute carrier family 47 member 2	Homo sapiens	90-97
26360835-6	2015	Transcellular pramipexole transport was investigated in MDCK cells single- or double-transfected with OCT2 and/or MATE1 and in Co cells, separating a basal from an apical compartment in a model for renal tubular secretion.	Pramipexole	14-25	solute carrier family 22 member 2	Canis lupus familiaris	102-106
26360835-6	2015	Transcellular pramipexole transport was investigated in MDCK cells single- or double-transfected with OCT2 and/or MATE1 and in Co cells, separating a basal from an apical compartment in a model for renal tubular secretion.	Pramipexole	14-25	solute carrier family 47 member 1	Homo sapiens	114-119
26360835-7	2015	Pramipexole uptake was 1.6-, 1.1-, or 1.6-folds in cells overexpressing OCT2, MATE1 or MATE2-K, respectively as compared to Co cells (p&lt;0.05).	Pramipexole	0-11	solute carrier family 22 member 2	Canis lupus familiaris	72-76
26360835-7	2015	Pramipexole uptake was 1.6-, 1.1-, or 1.6-folds in cells overexpressing OCT2, MATE1 or MATE2-K, respectively as compared to Co cells (p&lt;0.05).	Pramipexole	0-11	solute carrier family 47 member 1	Homo sapiens	78-83
26360835-7	2015	Pramipexole uptake was 1.6-, 1.1-, or 1.6-folds in cells overexpressing OCT2, MATE1 or MATE2-K, respectively as compared to Co cells (p&lt;0.05).	Pramipexole	0-11	solute carrier family 47 member 2	Homo sapiens	87-94
26360835-8	2015	In transcellular transport experiments, intracellular pramipexole accumulation was 1.7-folds in MDCK-OCT2 (p&lt;0.001), and transcellular pramipexole transport was 2.2- and 4.0-folds in MDCK-MATE1 and MDCK-OCT2-MATE1 cells as compared to Co cells (p&lt;0.001).	Pramipexole	54-65	solute carrier family 22 member 2	Canis lupus familiaris	96-105
26360835-8	2015	In transcellular transport experiments, intracellular pramipexole accumulation was 1.7-folds in MDCK-OCT2 (p&lt;0.001), and transcellular pramipexole transport was 2.2- and 4.0-folds in MDCK-MATE1 and MDCK-OCT2-MATE1 cells as compared to Co cells (p&lt;0.001).	Pramipexole	54-65	solute carrier family 22 member 2	Canis lupus familiaris	101-105
26360835-9	2015	Transcellular pramipexole transport was pH dependent and inhibited by cimetidine with IC50 values of 12muM and 5.5muM in MATE1 and OCT2-MATE1 cells, respectively.	Pramipexole	14-25	solute carrier family 47 member 1	Homo sapiens	121-126
26360835-9	2015	Transcellular pramipexole transport was pH dependent and inhibited by cimetidine with IC50 values of 12muM and 5.5muM in MATE1 and OCT2-MATE1 cells, respectively.	Pramipexole	14-25	solute carrier family 22 member 2	Canis lupus familiaris	131-135
26360835-9	2015	Transcellular pramipexole transport was pH dependent and inhibited by cimetidine with IC50 values of 12muM and 5.5muM in MATE1 and OCT2-MATE1 cells, respectively.	Pramipexole	14-25	solute carrier family 47 member 1	Homo sapiens	136-141
26360835-10	2015	Taken together, coordinate activity of OCT2-mediated uptake and MATE-mediated efflux determines pramipexole renal secretion.	Pramipexole	96-107	solute carrier family 22 member 2	Canis lupus familiaris	39-43
26360835-11	2015	Reduced OCT2 or MATE transport activity due to genetic variation or drug-drug interactions may affect pramipexole renal secretion.	Pramipexole	102-113	solute carrier family 22 member 2	Canis lupus familiaris	8-12
25739024-9	2015	Chronic pramipexole increased BDNF mRNA, but decreased trkB mRNA in the VTA in lesioned rats.	Pramipexole	8-19	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	55-59
25739024-11	2015	The present study indicates that both the 6-OHDA-induced dopaminergic lesion and chronic pramipexole influence BDNF signalling in limbic structures, which may be related to their pro-depressive and antidepressant activity in rats, respectively.	Pramipexole	89-100	brain-derived neurotrophic factor	Rattus norvegicus	111-115
25076559-8	2014	Moreover, type 2 iodothyronine deiodinase (Dio2) expression in porcine VICs treated with pergolide was shown, by a global analysis of mRNA, to be markedly increased compared to that induced by pramipexole.	Pramipexole	193-204	iodothyronine deiodinase 2	Homo sapiens	43-47
25514384-0	2015	Pramipexole protects dopaminergic neurons through paraplegin against 6-hydroxydopamine.	Pramipexole	0-11	SPG7 matrix AAA peptidase subunit, paraplegin	Homo sapiens	50-60
25514384-8	2015	However, the D3 receptor agonist, pramipexole, protected TH reactivity and restored paraplegin expression to the control level in the presence of 6-OHDA.	Pramipexole	34-45	SPG7 matrix AAA peptidase subunit, paraplegin	Homo sapiens	84-94
24965504-4	2014	There was a strong association between renal function (eGFR) and dexpramipexole CLr.	Pramipexole	65-79	epidermal growth factor receptor	Homo sapiens	55-59
25511804-4	2015	We show that prolonged administration of pramipexole (0.1mg/kg/day, 6 to 21 days), a preferential D3R agonist, leads to a decrease in DA uptake in mouse striatum that reflects a reduction in DAT affinity for DA in the absence of any change in DAT density or subcellular distribution.	Pramipexole	41-52	dopamine receptor D3	Mus musculus	98-101
25511804-4	2015	We show that prolonged administration of pramipexole (0.1mg/kg/day, 6 to 21 days), a preferential D3R agonist, leads to a decrease in DA uptake in mouse striatum that reflects a reduction in DAT affinity for DA in the absence of any change in DAT density or subcellular distribution.	Pramipexole	41-52	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	191-194
25511804-4	2015	We show that prolonged administration of pramipexole (0.1mg/kg/day, 6 to 21 days), a preferential D3R agonist, leads to a decrease in DA uptake in mouse striatum that reflects a reduction in DAT affinity for DA in the absence of any change in DAT density or subcellular distribution.	Pramipexole	41-52	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	243-246
25511804-5	2015	The effect of pramipexole was absent in mice with genetically-deleted D3R (D3R(-/-)), yet unaffected in mice genetically deprived of D2R (D2R(-/-)).	Pramipexole	14-25	dopamine receptor D3	Mus musculus	70-73
25511804-5	2015	The effect of pramipexole was absent in mice with genetically-deleted D3R (D3R(-/-)), yet unaffected in mice genetically deprived of D2R (D2R(-/-)).	Pramipexole	14-25	dopamine receptor D3	Mus musculus	75-78
25511804-6	2015	Pramipexole treatment induced a physical interaction between D3R and DAT, as assessed by co-immunoprecipitation and in situ proximity ligation assay.	Pramipexole	0-11	dopamine receptor D3	Mus musculus	61-72
25076559-10	2014	CONCLUSION: There were substantial differences (increased [3H]thymidine incorporation, and Dio2 expression) between pergolide and pramipexole, which might correlate with the mechanism of heart valve disease onset.	Pramipexole	130-141	iodothyronine deiodinase 2	Homo sapiens	91-95
23631878-4	2013	Dopamine and dopamine D2-like receptor agonists such as pramipexole and quinpirole reduced the formation of TRAP-positive multi-nucleated cells, cathepsin K mRNA expression, and pit formation area in vitro.	Pramipexole	56-67	cathepsin K	Homo sapiens	145-156
24289818-7	2014	Among the studied drugs, aripiprazole and pramipexole were found to be the most active one for hCA I (IC50: 3.64 and 5.37 muM) and hCA II (IC50: 4.16 and 4.81 muM) activity, respectively.	Pramipexole	42-53	carbonic anhydrase 1	Homo sapiens	95-100
24289818-7	2014	Among the studied drugs, aripiprazole and pramipexole were found to be the most active one for hCA I (IC50: 3.64 and 5.37 muM) and hCA II (IC50: 4.16 and 4.81 muM) activity, respectively.	Pramipexole	42-53	latexin	Homo sapiens	122-125
24289818-7	2014	Among the studied drugs, aripiprazole and pramipexole were found to be the most active one for hCA I (IC50: 3.64 and 5.37 muM) and hCA II (IC50: 4.16 and 4.81 muM) activity, respectively.	Pramipexole	42-53	carbonic anhydrase 2	Homo sapiens	131-137
23681749-0	2013	Pramipexole reduces phosphorylation of alpha-synuclein at serine-129.	Pramipexole	0-11	synuclein alpha	Homo sapiens	39-54
23681749-7	2013	The present study demonstrates that PPX inhibits the phosphorylation of alpha-synuclein and that this is independent of dopamine receptor activation.	Pramipexole	36-39	synuclein alpha	Homo sapiens	72-87
23681749-10	2013	Thus, PPX decreases the phosphorylation of alpha-synuclein, and this mechanism may contribute to its protective properties in PD models.	Pramipexole	6-9	synuclein alpha	Homo sapiens	43-58
23631981-1	2013	A previous clinical trial studied the effect of long-term treatment with levodopa (LD) or the dopamine agonist pramipexole (PPX) on disease progression in Parkinson disease using SPECT with the dopamine transporter (DAT)-radioligand [(123)I]beta-CIT as surrogate marker.	Pramipexole	111-122	solute carrier family 6 member 3	Homo sapiens	194-214
23631981-1	2013	A previous clinical trial studied the effect of long-term treatment with levodopa (LD) or the dopamine agonist pramipexole (PPX) on disease progression in Parkinson disease using SPECT with the dopamine transporter (DAT)-radioligand [(123)I]beta-CIT as surrogate marker.	Pramipexole	111-122	solute carrier family 6 member 3	Homo sapiens	216-219
24116342-4	2013	METHODS: We present an illustrative patient with concomitant RLS and migraine who showed improvement in her headache frequency and RLS symptoms following immediate-release pramipexole (P-IR) treatment and provide review results from the medical records of patients who experienced both migraines and RLS in our previous cross-sectional study.	Pramipexole	172-183	pirin	Homo sapiens	184-189
24289818-7	2014	Among the studied drugs, aripiprazole and pramipexole were found to be the most active one for hCA I (IC50: 3.64 and 5.37 muM) and hCA II (IC50: 4.16 and 4.81 muM) activity, respectively.	Pramipexole	42-53	latexin	Homo sapiens	159-162
23643745-6	2013	Amisulpride also attenuated the hypolocomotion induced by the D2/D3 receptor agonist pramipexole and dopamine precursor l-3,4-dihydroxyphenylalanine, whereas raclopride (and S33084) worsened it.	Pramipexole	85-96	dopamine receptor D2	Mus musculus	62-76
23241649-5	2013	Furthermore, we tested the sensitivity of PPX-induced CFL to CIM and to the 5HT2c antagonist SB242084.	Pramipexole	42-45	5-hydroxytryptamine receptor 2C	Rattus norvegicus	76-81
23483198-1	2013	RATIONALE: Pramipexole, a D2/D3 dopamine receptor agonist, has been implicated in the development of impulse control disorders in patients with Parkinson"s disease.	Pramipexole	11-22	dopamine receptor D3	Homo sapiens	29-49
23950645-3	2013	In this meta-analysis, we summarized the efficacy and tolerability of pramipexole in treatment for primary RLS.	Pramipexole	70-81	RLS1	Homo sapiens	107-110
23357086-2	2013	Recent studies have reported that the dopamine D2/D3 receptor agonist pramipexole exerts an antidepressant-like effect in the chronic mild stress model and in the behavioral despair model, suggesting dopamine D3 receptor may be an important target for antidepressant actions.	Pramipexole	70-81	dopamine receptor D3	Mus musculus	200-220
23950645-2	2013	Pramipexole, a potent dopamine D2/3 agonist, is recommended as "effective" in the short-term and "possibly effective" in the long-term treatment of primary RLS in the European guidelines on management of RLS.	Pramipexole	0-11	RLS1	Homo sapiens	156-159
23311775-0	2013	Age-dependent dystonia in striatal Ggamma7 deficient mice is reversed by the dopamine D2 receptor agonist pramipexole.	Pramipexole	106-117	dopamine receptor D2	Mus musculus	77-97
23311775-6	2013	Taking advantage of the finding of D2R down-regulation in Ggamma7 knockout mice and the dopamine-mediated synergistic relationship in the control of locomotion between D2R-striatopallidal and D1R-stritonigral neurons, we hypothesized that D2-agonist pramipexole would reverse behavioral dyskinesia caused by defective D1R/Galphaolf signaling.	Pramipexole	250-261	dopamine receptor D1	Mus musculus	192-195
23950645-2	2013	Pramipexole, a potent dopamine D2/3 agonist, is recommended as "effective" in the short-term and "possibly effective" in the long-term treatment of primary RLS in the European guidelines on management of RLS.	Pramipexole	0-11	RLS1	Homo sapiens	204-207
23950645-4	2013	Results of this meta-analysis showed a favorable effect of pramipexole versus placebo on RLS symptoms (mean change on International RLS Study Group Rating Scale [IRLS] score: mean difference [MD] = -5.96; 95% confidence interval [CI]: -7.79 to -4.41, P &lt; 0.00001) and sleep quality (pooled standard mean difference [SMD] = -0.48, 95% CI: -0.61 to -0.35, P &lt; 0.00001).	Pramipexole	59-70	RLS1	Homo sapiens	89-92
23950645-4	2013	Results of this meta-analysis showed a favorable effect of pramipexole versus placebo on RLS symptoms (mean change on International RLS Study Group Rating Scale [IRLS] score: mean difference [MD] = -5.96; 95% confidence interval [CI]: -7.79 to -4.41, P &lt; 0.00001) and sleep quality (pooled standard mean difference [SMD] = -0.48, 95% CI: -0.61 to -0.35, P &lt; 0.00001).	Pramipexole	59-70	RLS1	Homo sapiens	132-135
22325981-4	2012	Recently, we demonstrated that the dopamine agonist pramipexole improves the therapeutic effect of L-dopa in 6-pyruvoyl tetrahydropterin synthase (PTPS) deficiency, the most common disorder of BH4 metabolism.	Pramipexole	52-63	6-pyruvoyltetrahydropterin synthase	Homo sapiens	147-151
22153972-2	2012	Pramipexole was generally well-tolerated (82% trial-completion), and yielded greater decreases in PANSS-total scores (drug/placebo=2.1; p=0.04), with similar decreases in PANSS positive and negative scores and 6.7-fold greater reduction of serum prolactin concentrations compared to placebo.	Pramipexole	0-11	prolactin	Homo sapiens	246-255
22808933-8	2012	Moreover, further studies should investigate the extended-release formulation of ropinirole and pramipexole in RLS patients affected by all day long distressing symptoms.	Pramipexole	96-107	RLS1	Homo sapiens	111-114
22333559-7	2012	Fourteen patients with RBD (80.0%) achieved symptomatic improvement of RBD with pramipexole treatment, which reduced REM density and PLM index during non-REM sleep despite the unchanged amount of RWA.	Pramipexole	80-91	FXYD domain containing ion transport regulator 1	Homo sapiens	133-136
22227455-1	2012	BACKGROUND: In rats, prepulse inhibition (PPI) of acoustic startle is disrupted by systemic administration of dopaminergic agonists, such as the dopamine D3 receptor (D3R)-preferential agonist pramipexole (PPX).	Pramipexole	193-204	dopamine receptor D3	Rattus norvegicus	145-165
22227455-1	2012	BACKGROUND: In rats, prepulse inhibition (PPI) of acoustic startle is disrupted by systemic administration of dopaminergic agonists, such as the dopamine D3 receptor (D3R)-preferential agonist pramipexole (PPX).	Pramipexole	206-209	dopamine receptor D3	Rattus norvegicus	145-165
22101745-7	2011	RESULTS: Both pramipexole and dual-release L/B were effective in reducing PLM and RLS symptoms.	Pramipexole	14-25	FXYD domain containing ion transport regulator 1	Homo sapiens	74-77
22023785-10	2012	CONCLUSION: Chronic PPX administration led to a net enhancement in DA and 5-HT neurotransmission, as indicated by the increased tonic activation of postsynaptic D2 and 5-HT1A receptors in forebrain structures.	Pramipexole	20-23	5-hydroxytryptamine receptor 1A	Rattus norvegicus	168-174
22986363-0	2012	Pramipexole upregulates dopamine receptor D2 and D3 expression in rat striatum.	Pramipexole	0-11	solute carrier family 3 member 1	Rattus norvegicus	42-51
23391874-2	2012	Our previous study demonstrated that pergolide and pramipexole stimulated elevation of plasma arginine vasopressin (AVP) levels in some patients with Parkinson"s disease (PD), but that levodopa/carbidopa (300/30 mg/day) did not affect plasma AVP levels in treatment-naive PD patients.	Pramipexole	51-62	arginine vasopressin	Homo sapiens	103-114
22467109-2	2012	Our previous study demonstrated that in some patients with Parkinson"s disease (PD), pergolide and pramipexole stimulate elevations of plasma arginine vasopressin (AVP) levels even at doses that are lower than the ordinary maintenance dose.	Pramipexole	99-110	arginine vasopressin	Homo sapiens	151-162
21272591-8	2011	A 24 h treatment with PPX does not modify the morphology of neurosphere-derived cells, but causes an increase of glial fibrillary acidic protein (GFAP)-positive cells, an effect sensitive to both D2 and D3 antagonism.	Pramipexole	22-25	glial fibrillary acidic protein	Mus musculus	113-144
21683731-2	2011	In mice, the dopamine D3 receptor-preferential agonist pramipexole (PPX) alters locomotor activity in a biphasic manner at doses that have no effect on PPI.	Pramipexole	55-66	dopamine receptor D3	Mus musculus	13-33
21683731-2	2011	In mice, the dopamine D3 receptor-preferential agonist pramipexole (PPX) alters locomotor activity in a biphasic manner at doses that have no effect on PPI.	Pramipexole	68-71	dopamine receptor D3	Mus musculus	13-33
21892895-8	2011	Pramipexole has a very low affinity for serotoninergic 5-HT2A and 5-HT2B receptors, as well as D1-type receptors.	Pramipexole	0-11	5-hydroxytryptamine receptor 2A	Homo sapiens	55-61
21272591-8	2011	A 24 h treatment with PPX does not modify the morphology of neurosphere-derived cells, but causes an increase of glial fibrillary acidic protein (GFAP)-positive cells, an effect sensitive to both D2 and D3 antagonism.	Pramipexole	22-25	glial fibrillary acidic protein	Mus musculus	146-150
21408026-1	2011	The purpose of this study was to determine the binding sites of pramipexole in extrastriatal dopaminergic regions because its antidepressive effects have been speculated to occur by activating the dopamine D(2) receptor subfamily in extrastriatal areas.	Pramipexole	64-75	dopamine receptor D2	Homo sapiens	197-219
20925067-1	2011	To compare the safety and efficacy of low dosages of pramipexole given twice daily (bid) in early Parkinson"s disease (PD) with those of a standard 3 times daily (tid) regimen in a randomized, double-blind, placebo controlled trial involving 311 early PD patients not receiving dopaminergic treatment.	Pramipexole	53-64	BH3 interacting domain death agonist	Homo sapiens	84-87
20680652-1	2011	Substrates for the Organic Cation Transporter 1, encoded by the SLC22A1 gene, are metformin, amantadine, pramipexole, and, possibly, levodopa.	Pramipexole	105-116	solute carrier family 22 member 1	Homo sapiens	19-47
20680652-1	2011	Substrates for the Organic Cation Transporter 1, encoded by the SLC22A1 gene, are metformin, amantadine, pramipexole, and, possibly, levodopa.	Pramipexole	105-116	solute carrier family 22 member 1	Homo sapiens	64-71
20697890-3	2010	Here we used multi-tracer positron emission tomography imaging and a unilateral 6-hydroxydopamine (6-OHDA) rat model of PD to evaluate in vivo the effects of chronic levodopa and pramipexole treatments on measurements of vesicular monoamine transporter type 2 (VMAT2), dopamine transporter (DAT) levels, and on levodopa-induced changes in synaptic DA levels [Delta(DA)].	Pramipexole	179-190	solute carrier family 18 member A2	Rattus norvegicus	221-259
20965780-0	2011	Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood.	Pramipexole	20-31	RLS1	Homo sapiens	74-77
20965780-0	2011	Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood.	Pramipexole	20-31	RLS1	Homo sapiens	83-86
20965780-2	2011	We investigated the change of RLS-related mood impairment during treatment of RLS with pramipexole, a dopamine D(3)/D(2) agonist.	Pramipexole	87-98	RLS1	Homo sapiens	30-33
20965780-2	2011	We investigated the change of RLS-related mood impairment during treatment of RLS with pramipexole, a dopamine D(3)/D(2) agonist.	Pramipexole	87-98	RLS1	Homo sapiens	78-81
20965780-10	2011	CONCLUSIONS: In patients with RLS-related mood disturbance, pramipexole improved RLS while also improving RLS-related mood impairment.	Pramipexole	60-71	RLS1	Homo sapiens	30-33
20965780-10	2011	CONCLUSIONS: In patients with RLS-related mood disturbance, pramipexole improved RLS while also improving RLS-related mood impairment.	Pramipexole	60-71	RLS1	Homo sapiens	81-84
20965780-10	2011	CONCLUSIONS: In patients with RLS-related mood disturbance, pramipexole improved RLS while also improving RLS-related mood impairment.	Pramipexole	60-71	RLS1	Homo sapiens	81-84
21044864-12	2011	CONCLUSIONS: Pramipexole produced long-term improvement of the RLS-like symptoms in our proposed animal model, caused a partial recovery of spinal iron deficiency, and modestly increased D1 receptor affinity.	Pramipexole	13-24	dopamine receptor D1	Mus musculus	187-198
20697890-3	2010	Here we used multi-tracer positron emission tomography imaging and a unilateral 6-hydroxydopamine (6-OHDA) rat model of PD to evaluate in vivo the effects of chronic levodopa and pramipexole treatments on measurements of vesicular monoamine transporter type 2 (VMAT2), dopamine transporter (DAT) levels, and on levodopa-induced changes in synaptic DA levels [Delta(DA)].	Pramipexole	179-190	solute carrier family 18 member A2	Rattus norvegicus	261-266
20697890-3	2010	Here we used multi-tracer positron emission tomography imaging and a unilateral 6-hydroxydopamine (6-OHDA) rat model of PD to evaluate in vivo the effects of chronic levodopa and pramipexole treatments on measurements of vesicular monoamine transporter type 2 (VMAT2), dopamine transporter (DAT) levels, and on levodopa-induced changes in synaptic DA levels [Delta(DA)].	Pramipexole	179-190	solute carrier family 6 member 3	Rattus norvegicus	269-289
20697890-3	2010	Here we used multi-tracer positron emission tomography imaging and a unilateral 6-hydroxydopamine (6-OHDA) rat model of PD to evaluate in vivo the effects of chronic levodopa and pramipexole treatments on measurements of vesicular monoamine transporter type 2 (VMAT2), dopamine transporter (DAT) levels, and on levodopa-induced changes in synaptic DA levels [Delta(DA)].	Pramipexole	179-190	solute carrier family 6 member 3	Rattus norvegicus	291-294
19396436-0	2009	Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson"s disease patients.	Pramipexole	64-75	dopamine receptor D2	Homo sapiens	19-23
20123564-7	2009	A placebo-controlled study of pramipexole in dPD is ongoing.	Pramipexole	30-41	dachs	Drosophila melanogaster	45-48
20021407-5	2009	Six antagonists, Bromocriptine, Cabergoline, Etilevodopa, Lysuride, Melevodopa and Pramipexole, were found more potent for binding and the active amino acids residues were identified (http://www.rcsb.org/pdb/) in A2A receptor.	Pramipexole	83-94	immunoglobulin kappa variable 2D-29	Homo sapiens	213-216
20635141-1	2010	Pramipexole (PPX), a dopamine (DA) receptor D3 preferring agonist, has been used as monotherapy or adjunct therapy to treat Parkinson"s disease (PD) for many years.	Pramipexole	0-11	dopamine receptor D3	Mus musculus	21-46
20635141-1	2010	Pramipexole (PPX), a dopamine (DA) receptor D3 preferring agonist, has been used as monotherapy or adjunct therapy to treat Parkinson"s disease (PD) for many years.	Pramipexole	13-16	dopamine receptor D3	Mus musculus	21-46
20496886-2	2010	In rats, rOct1 and rOct2 contribute toward pramipexole excretion into urine.	Pramipexole	43-54	solute carrier family 22 member 1	Rattus norvegicus	9-14
20496886-2	2010	In rats, rOct1 and rOct2 contribute toward pramipexole excretion into urine.	Pramipexole	43-54	solute carrier family 22 member 2	Rattus norvegicus	19-24
20496886-3	2010	The objective of this study was to assess whether pramipexole is a substrate for human OCT1-3.	Pramipexole	50-61	solute carrier family 22 member 1	Homo sapiens	87-93
20496886-5	2010	hOCT2 transported pramipexole in a high affinity manner (K(t) = 15.4 +/- 4.1 microM, J(max) = 0.476 +/- 0.028 pmol/s/cm(2)).	Pramipexole	18-29	POU class 2 homeobox 2	Homo sapiens	0-5
20496886-6	2010	hOCT3 transported pramipexole in a low affinity manner (K(t) = 138 +/- 31 microM, J(max) = 1.10 +/- 0.08 pmol/s/cm(2)).	Pramipexole	18-29	solute carrier family 22 member 3	Homo sapiens	0-5
20496886-8	2010	The human intestinal absorption of pramipexole may involve transport by OCT3 and possibly OCT2.	Pramipexole	35-46	solute carrier family 22 member 3	Homo sapiens	72-76
20496886-8	2010	The human intestinal absorption of pramipexole may involve transport by OCT3 and possibly OCT2.	Pramipexole	35-46	POU class 2 homeobox 2	Homo sapiens	90-94
20496886-9	2010	OCT2- and OCT3-mediated transport of pramipexole have implications in the drug"s elimination from the kidney and distribution in the brain, respectively.	Pramipexole	37-48	POU class 2 homeobox 2	Homo sapiens	0-4
20496886-9	2010	OCT2- and OCT3-mediated transport of pramipexole have implications in the drug"s elimination from the kidney and distribution in the brain, respectively.	Pramipexole	37-48	solute carrier family 22 member 3	Homo sapiens	10-14
20122926-4	2010	Indeed, the dopamine precursor, l-dopa (1-10 mg/kg), and the D(3)/D(2) receptor agonist pramipexole (0.0001-0.001 mg/kg) promoted stepping activity in the drag test (a test for akinesia/bradykinesia).	Pramipexole	88-99	dopamine receptor D2	Mus musculus	66-79
20385162-1	2010	The preferential dopamine D3 receptor agonist pramipexole (PRA) disrupts prepulse inhibition (PPI) of acoustic startle, an operational measure of sensorimotor gating, in rats.	Pramipexole	46-57	dopamine receptor D3	Rattus norvegicus	17-37
19962941-5	2010	In all patients, variables on SIT did not show any differences between the two groups, whereas a significant improvement was shown in the pramipexole group compared with the placebo group for patients with a SIT-PLM index at baseline &gt;or=15.	Pramipexole	138-149	FXYD domain containing ion transport regulator 1	Homo sapiens	212-215
20120624-11	2010	In the RLS treatment group, a statistically significant dose effect was found for pramipexole in those subjects confirmed to have ICDs by both the questionnaire and phone interview.	Pramipexole	82-93	RLS1	Homo sapiens	7-10
19647776-7	2009	Pramipexole inhibited rotenone-induced DA neuronal death and motor deficits, and reduced immunoreactivity for alpha-synuclein.	Pramipexole	0-11	synuclein, alpha	Mus musculus	110-125
19647776-8	2009	In addition, pramipexole inhibited the in vitro oligomerization of human wild-type alpha-synuclein by H(2)O(2)plus cytochrome c.	Pramipexole	13-24	synuclein, alpha	Mus musculus	83-98
19647776-8	2009	In addition, pramipexole inhibited the in vitro oligomerization of human wild-type alpha-synuclein by H(2)O(2)plus cytochrome c.	Pramipexole	13-24	cytochrome c, somatic	Homo sapiens	115-127
19647776-12	2009	Furthermore, pramipexole increased Bcl-2 immunoreactivity in DA neurons in the SNpc.	Pramipexole	13-24	B cell leukemia/lymphoma 2	Mus musculus	35-40
19647776-13	2009	These results suggest that pramipexole may protect DA neurons against exposure to rotenone by chronic oral administration, and this effect is mediated by multiple functions including scavenging of *OH and induction of Bcl-2 protein.	Pramipexole	27-38	B cell leukemia/lymphoma 2	Mus musculus	218-223
20161553-2	2009	The standard treatment recommendations for these disorders are pharmacologic; most recently both conditions are most typically managed with pramipexole or ropinerole, which are FDA approved for the treatment of RLS.	Pramipexole	140-151	RLS1	Homo sapiens	211-214
19765187-7	2009	Treatment with either l-dopa or PPX in MPTP-treated mice led to significantly decreased expressions of JNK phosphorylation, Bax, and cytochrome c and to an increased level of Bcl-2 expression with a similar degree, compared with the levels in MPTP-only treated mice.	Pramipexole	32-35	mitogen-activated protein kinase 8	Mus musculus	103-106
19765187-7	2009	Treatment with either l-dopa or PPX in MPTP-treated mice led to significantly decreased expressions of JNK phosphorylation, Bax, and cytochrome c and to an increased level of Bcl-2 expression with a similar degree, compared with the levels in MPTP-only treated mice.	Pramipexole	32-35	BCL2-associated X protein	Mus musculus	124-127
19765187-7	2009	Treatment with either l-dopa or PPX in MPTP-treated mice led to significantly decreased expressions of JNK phosphorylation, Bax, and cytochrome c and to an increased level of Bcl-2 expression with a similar degree, compared with the levels in MPTP-only treated mice.	Pramipexole	32-35	B cell leukemia/lymphoma 2	Mus musculus	175-180
19704083-1	2009	OBJECTIVE: To report the efficacy, tolerability, and safety of the dopamine agonist pramipexole in a series of 5 patients affected by inherited 6-pyruvoyl tetrahydropterin synthase (PTPS) deficiency and needing l-3,4 dihydroxyphenylalanine (l-dopa) therapy.	Pramipexole	84-95	6-pyruvoyltetrahydropterin synthase	Homo sapiens	144-180
19704083-1	2009	OBJECTIVE: To report the efficacy, tolerability, and safety of the dopamine agonist pramipexole in a series of 5 patients affected by inherited 6-pyruvoyl tetrahydropterin synthase (PTPS) deficiency and needing l-3,4 dihydroxyphenylalanine (l-dopa) therapy.	Pramipexole	84-95	6-pyruvoyltetrahydropterin synthase	Homo sapiens	182-186
19704083-12	2009	CONCLUSIONS: The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.	Pramipexole	29-40	6-pyruvoyltetrahydropterin synthase	Homo sapiens	61-97
19396436-0	2009	Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson"s disease patients.	Pramipexole	64-75	dopamine receptor D3	Homo sapiens	28-32
19396436-1	2009	OBJECTIVE: To evaluate the impact of the DRD2 TaqIA and DRD3 Ser9Gly polymorphisms on the efficacy of pramipexole in treating patients with Parkinson"s disease (PD).	Pramipexole	102-113	dopamine receptor D2	Homo sapiens	41-45
19396436-1	2009	OBJECTIVE: To evaluate the impact of the DRD2 TaqIA and DRD3 Ser9Gly polymorphisms on the efficacy of pramipexole in treating patients with Parkinson"s disease (PD).	Pramipexole	102-113	dopamine receptor D3	Homo sapiens	56-60
19396436-7	2009	When the subjects were grouped by the DRD3 Ser9Gly polymorphism, the response rates for pramipexole treatment were significantly higher in the Ser/Ser group (60%) than in the group containing the Gly allele (13%).	Pramipexole	88-99	dopamine receptor D3	Homo sapiens	38-42
19396436-8	2009	There was a significant association between the DRD3 Ser9Gly polymorphism and response rate to pramipexole in PD patients (P = 0.024).	Pramipexole	95-106	dopamine receptor D3	Homo sapiens	48-52
19396436-10	2009	CONCLUSIONS: DRD3 Ser9Gly polymorphisms are significantly associated with the therapeutic efficacy of pramipexole in Chinese patients with PD.	Pramipexole	102-113	dopamine receptor D3	Homo sapiens	13-17
18455202-4	2008	Dopamine, as well as the dopamine receptor agonists pramipexole and quinpirole, acted as full agonists in the assay as reflected by their ability to elicit marked concentration dependent increases in the BRET signal signifying beta-arrestin2 recruitment to the D2 receptor.	Pramipexole	52-63	arrestin beta 2	Homo sapiens	227-241
21687007-7	2009	Accordingly, pramipexole has a higher selectivity for D4 receptor than other dopamine agonists.	Pramipexole	13-24	dopamine receptor D4	Homo sapiens	54-65
18598736-4	2008	Among the antiparkinsonian drugs tested, levodopa, bromocriptine, pergolide and pramipexole were ABCB1 substrates.	Pramipexole	80-91	ATP binding cassette subfamily B member 1A	Rattus norvegicus	97-102
18555604-4	2008	Pretreatment with 100 microM pramipexole rescued TH-positive neurons and MAP2-positive neurons from the toxicity of lactacystin.	Pramipexole	29-40	microtubule associated protein 2	Homo sapiens	73-77
18555604-10	2008	Pramipexole increased the levels of brain derived neurotrophic factor (BDNF) in the conditioned medium of astrocyte cultures.	Pramipexole	0-11	brain derived neurotrophic factor	Homo sapiens	36-69
18555604-10	2008	Pramipexole increased the levels of brain derived neurotrophic factor (BDNF) in the conditioned medium of astrocyte cultures.	Pramipexole	0-11	brain derived neurotrophic factor	Homo sapiens	71-75
18555604-12	2008	We demonstrated that pramipexole had the protective effect against lactacystin toxicity, mediated by a neurotrophic effect of astrocyte-produced factors including BDNF.	Pramipexole	21-32	brain derived neurotrophic factor	Homo sapiens	163-167
18611302-4	2008	Although two dopamine agonists, ropinirole and pramipexole, have been approved by the FDA for the treatment of RLS and are currently the first-line treatment for daily symptoms, there is very little information on the teratogenic risks of these new medications.	Pramipexole	47-58	RLS1	Homo sapiens	111-114
19220275-1	2009	AIMS: To assess the sleepiness induced by pramipexole, a D2/D3-dopamine receptor agonist commonly used in Parkinson"s disease and restless legs syndrome, without the problem of the confounding factors related to the disease.	Pramipexole	42-53	dopamine receptor D3	Homo sapiens	60-80
19750232-8	2009	The first line treatment for idiopathic RLS is represented by dopamine agonists, in particular nonergot-derived ropinirole and pramipexole, whereas ergot dopamine agonists (cabergoline and pergolide) are no longer in first-line use given the risks of cardiac valvulopathy.	Pramipexole	127-138	RLS1	Homo sapiens	40-43
20666116-3	2009	The dopamine agonists ropinirole and pramipexole are currently considered to be the agents of choice for the treatment of RLS.	Pramipexole	37-48	RLS1	Homo sapiens	122-125
18952497-0	2008	Effect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trial.	Pramipexole	10-21	RLS1	Homo sapiens	25-28
18952497-2	2008	Our goal was to test the ability of pramipexole to improve sleep in RLS patients and to reconfirm its efficacy for primary RLS symptoms.	Pramipexole	36-47	RLS1	Homo sapiens	68-71
18952497-10	2008	CONCLUSIONS: Pramipexole is effective and well-tolerated for RLS and related sleep disturbance.	Pramipexole	13-24	RLS1	Homo sapiens	61-64
18537487-9	2008	Several large, double-blind, placebo-controlled studies have demonstrated that dopamine agonists, such as ropinirole and pramipexole, are an efficacious first-line therapy for the treatment of RLS symptoms.	Pramipexole	121-132	RLS1	Homo sapiens	193-196
17578485-10	2007	Pramipexole reduced prolactin and increased GH concentrations.	Pramipexole	0-11	prolactin	Homo sapiens	20-29
17578485-10	2007	Pramipexole reduced prolactin and increased GH concentrations.	Pramipexole	0-11	growth hormone 1	Homo sapiens	44-46
17534955-2	2007	In the CALM-PD trial, subjects were initially randomized to levodopa or pramipexole and could later add levodopa if needed.	Pramipexole	72-83	synaptosome associated protein 91	Homo sapiens	7-11
16802163-7	2006	RESULTS: Pramipexole reduced alertness and pupillary light reflex response amplitude, tended to reduce core temperature, reduced prolactin levels and increased GH levels.	Pramipexole	9-20	growth hormone 1	Homo sapiens	160-162
17356338-5	2007	A subsequent therapeutic trial with pramipexole, a dopamine agonist with preferential D3 dopamine receptor activity, resulted in the recurrence of PG.	Pramipexole	36-47	dopamine receptor D3	Homo sapiens	86-106
17161393-3	2007	Pramipexole, a dopamine D2/D3 receptor agonist used clinically in the treatment of Parkinson disease, did not affect glutamate-induced calcium influx but blocked dopaminergic neuronal death induced by glutamate.	Pramipexole	0-11	dopamine receptor D2	Homo sapiens	15-38
16401653-8	2006	Pramipexole reduced alertness, caused pupil dilatation, increased heart rate, reduced prolactin and thyroid stimulating hormone, and increased growth hormone level.	Pramipexole	0-11	prolactin	Homo sapiens	86-95
16401653-8	2006	Pramipexole reduced alertness, caused pupil dilatation, increased heart rate, reduced prolactin and thyroid stimulating hormone, and increased growth hormone level.	Pramipexole	0-11	growth hormone 1	Homo sapiens	143-157
16930379-4	2006	Amongst the non-ergoline dopamine agonists, pramipexole has been reported to reduce RLS symptoms, but robust trial data are limited.	Pramipexole	44-55	RLS1	Homo sapiens	84-87
16982285-9	2006	The occurrence of dyskinesia may be linked to stimulation of the dopamine D(1) receptor, for which cabergoline and pergolide have a similar and relatively high affinity; bromocriptine, pramipexole, and ropinirole have been associated with a lower risk of dyskinesias.	Pramipexole	185-196	dopamine receptor D1	Homo sapiens	65-87
16675366-14	2006	The dopamine agonists used to treat Parkinson"s disease--bromocriptine, pergolide, pramipexole, ropinerole--usually reverse antipsychotic-induced prolactin increases without compromising psychiatric effectiveness.	Pramipexole	83-94	prolactin	Homo sapiens	146-155
16963794-5	2006	Moreover, progesterone and BD 1047 (a sigma(1) receptor antagonist) counteracted the antidepressant-like effect induced by co-administration of pramipexole and sertraline (but not pramipexole and fluoxetine).	Pramipexole	144-155	sigma non-opioid intracellular receptor 1	Rattus norvegicus	38-55
16362428-6	2006	In PC12 cells, pramipexole inhibited H2O2-induced lactate dehydrogenase (LDH) leakage, as well as H2O2-induced cytochrome c release and caspase-3 activation with the resultant apoptosis.	Pramipexole	15-26	caspase 3	Rattus norvegicus	136-145
16362428-8	2006	Pramipexole inhibited H2O2-induced JNK and p38 MAP kinase, but not ERK1/2 phosphorylation.	Pramipexole	0-11	mitogen-activated protein kinase 8	Rattus norvegicus	35-38
16362428-8	2006	Pramipexole inhibited H2O2-induced JNK and p38 MAP kinase, but not ERK1/2 phosphorylation.	Pramipexole	0-11	mitogen activated protein kinase 14	Rattus norvegicus	43-57
16362428-9	2006	Furthermore, in these cells experiments with a fluorescent probe, 2-[6-(4"-amino)phenoxy-3H-xanthen-3-on-9-yl]benzoic acid, revealed that pramipexole, the JNK inhibitor SP600125 and the p38 MAP kinase inhibitor SB203580 inhibited the generation of H2O2-induced reactive oxygen species.	Pramipexole	138-149	mitogen-activated protein kinase 8	Rattus norvegicus	155-158
16362428-9	2006	Furthermore, in these cells experiments with a fluorescent probe, 2-[6-(4"-amino)phenoxy-3H-xanthen-3-on-9-yl]benzoic acid, revealed that pramipexole, the JNK inhibitor SP600125 and the p38 MAP kinase inhibitor SB203580 inhibited the generation of H2O2-induced reactive oxygen species.	Pramipexole	138-149	mitogen activated protein kinase 14	Rattus norvegicus	186-200
16362428-11	2006	These results suggest that pramipexole exerts a protective effect against oxidative stress-induced PC12 cell death in part through an inhibition of JNK and p38 MAP kinase.	Pramipexole	27-38	mitogen-activated protein kinase 8	Rattus norvegicus	148-151
16362428-11	2006	These results suggest that pramipexole exerts a protective effect against oxidative stress-induced PC12 cell death in part through an inhibition of JNK and p38 MAP kinase.	Pramipexole	27-38	mitogen activated protein kinase 14	Rattus norvegicus	156-159
16088951-3	2005	The K(i) values for the human cloned D2(High) and D3(High) receptors, respectively, were 19 and 9 nM for pramipexole, 0.24 and 0.6 nM for +PHNO, 0.7 and 1.3 nM for bromocriptine, 0.5 and 2.6 nM for apomorphine, and 0.09 and 0.25 nM for (-)N-propylnorapomorphine.	Pramipexole	105-116	iodothyronine deiodinase 3	Homo sapiens	50-68
17314491-1	2006	BACKGROUND: Pramipexole is a D3 dopaminergic agonist that has shown a major effect on both sensory and motor manifestations of restless legs syndrome (RLS) in long-term trials.	Pramipexole	12-23	RLS1	Homo sapiens	151-154
17314491-3	2006	OBJECTIVE: To evaluate the acute effect of a low dosage of pramipexole (0.125 mg) on sensory symptoms and motor signs of RLS and on the macro- and microstructure of sleep.	Pramipexole	59-70	RLS1	Homo sapiens	121-124
17314491-6	2006	Pramipexole 0.125 mg was administered before the second night at 9:00 p.m. A visual analog scale was used to assess the sensory symptoms of RLS.	Pramipexole	0-11	RLS1	Homo sapiens	140-143
17314491-8	2006	RESULTS: After the acute administration of pramipexole, we observed a significant improvement of the sensory symptoms and motor signs of RLS.	Pramipexole	43-54	RLS1	Homo sapiens	137-140
17314491-10	2006	CONCLUSIONS: Our results suggest that low doses of pramipexole are effective in reducing sensory symptoms and motor signs of RLS, even after the first administration.	Pramipexole	51-62	RLS1	Homo sapiens	125-128
15640376-0	2005	Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney.	Pramipexole	37-48	solute carrier family 22 member 1	Rattus norvegicus	84-88
15640376-7	2005	These results demonstrate that both rOCT1 and rOCT2 are involved in the renal uptake of pramipexole across the basolateral membrane of the proximal tubular epithelial cells.	Pramipexole	88-99	solute carrier family 22 member 2	Rattus norvegicus	46-51
15640376-0	2005	Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney.	Pramipexole	37-48	solute carrier family 22 member 2	Rattus norvegicus	93-97
15640376-2	2005	The uptake of [14C]pramipexole by Xenopus oocytes injected with complementary RNA of either rat organic cation transporter (rOCT) 1 or rOCT2 was significantly higher than that by water-injected oocytes: the kinetic parameters, K(m) and V(max), of pramipexole uptake were 49.5 muM and 234 pmol/60 min/oocyte for rOCT1, and 16.9 microM and 12.8 pmol/60 min/oocyte for rOCT2.	Pramipexole	19-30	solute carrier family 22 member 2	Rattus norvegicus	135-140
15640376-2	2005	The uptake of [14C]pramipexole by Xenopus oocytes injected with complementary RNA of either rat organic cation transporter (rOCT) 1 or rOCT2 was significantly higher than that by water-injected oocytes: the kinetic parameters, K(m) and V(max), of pramipexole uptake were 49.5 muM and 234 pmol/60 min/oocyte for rOCT1, and 16.9 microM and 12.8 pmol/60 min/oocyte for rOCT2.	Pramipexole	19-30	solute carrier family 22 member 1	Rattus norvegicus	311-316
15640376-2	2005	The uptake of [14C]pramipexole by Xenopus oocytes injected with complementary RNA of either rat organic cation transporter (rOCT) 1 or rOCT2 was significantly higher than that by water-injected oocytes: the kinetic parameters, K(m) and V(max), of pramipexole uptake were 49.5 muM and 234 pmol/60 min/oocyte for rOCT1, and 16.9 microM and 12.8 pmol/60 min/oocyte for rOCT2.	Pramipexole	19-30	solute carrier family 22 member 2	Rattus norvegicus	366-371
15640376-6	2005	The IC50 values of procainamide and corticosterone for the uptake of [14C]pramipexole by rOCT1, rOCT2, and kidney slices were 7.7, 167.0, and 47.0 microM and 163.7, 10.7, and 47.7 microM, respectively.	Pramipexole	74-85	solute carrier family 22 member 1	Rattus norvegicus	89-94
15640376-6	2005	The IC50 values of procainamide and corticosterone for the uptake of [14C]pramipexole by rOCT1, rOCT2, and kidney slices were 7.7, 167.0, and 47.0 microM and 163.7, 10.7, and 47.7 microM, respectively.	Pramipexole	74-85	solute carrier family 22 member 2	Rattus norvegicus	96-101
15640376-7	2005	These results demonstrate that both rOCT1 and rOCT2 are involved in the renal uptake of pramipexole across the basolateral membrane of the proximal tubular epithelial cells.	Pramipexole	88-99	solute carrier family 22 member 1	Rattus norvegicus	36-41
15569251-5	2004	However, pramipexole reduced caspase-3 activation, decreased the release of cytochrome c and prevented the fall in the mitochondrial membrane potential induced by MPP+ and rotenone.	Pramipexole	9-20	caspase 3	Homo sapiens	29-38
15569251-5	2004	However, pramipexole reduced caspase-3 activation, decreased the release of cytochrome c and prevented the fall in the mitochondrial membrane potential induced by MPP+ and rotenone.	Pramipexole	9-20	cytochrome c, somatic	Homo sapiens	76-88
15473989-0	2004	Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells.	Pramipexole	98-109	brain derived neurotrophic factor	Homo sapiens	48-52
14655914-2	2003	DESIGN: Retrospective review of the records of consecutive patients treated with pramipexole for RLS.	Pramipexole	81-92	RLS1	Homo sapiens	97-100
14985923-12	2004	CONCLUSIONS: Taken together, these studies suggest that the D2 receptor rather than the D3 receptor is important for the antidepressant-like activity observed for pramipexole in the mouse forced swim test.	Pramipexole	163-174	dopamine receptor D2	Mus musculus	60-71
15473989-3	2004	To test if the D(3) receptor preferring agonists S32504 and pramipexole act through D(2) or D(3) receptors and via brain-derived neurotrophic factor (BDNF)-dependent pathways, we utilized a terminally differentiated neuroblastoma SH-SY5Y cell line exhibiting a dopaminergic phenotype.	Pramipexole	60-71	brain derived neurotrophic factor	Homo sapiens	115-148
15473989-3	2004	To test if the D(3) receptor preferring agonists S32504 and pramipexole act through D(2) or D(3) receptors and via brain-derived neurotrophic factor (BDNF)-dependent pathways, we utilized a terminally differentiated neuroblastoma SH-SY5Y cell line exhibiting a dopaminergic phenotype.	Pramipexole	60-71	brain derived neurotrophic factor	Homo sapiens	150-154
15473989-8	2004	Antibody directed against BDNF concentration-dependently blocked both the neuroprotective effects of BDNF and those of pramipexole and S32504 against MPP(+).	Pramipexole	119-130	brain derived neurotrophic factor	Homo sapiens	26-30
15473914-0	2004	Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson"s disease, and downregulates the dopamine transporter via the D3 receptor.	Pramipexole	9-20	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	110-130
15473914-2	2004	We also determined whether subchronic treatment with pramipexole regulates dopamine transporter function, thereby reducing intracellular transport of the active metabolite of MPTP, 1-methyl-4-phenylpyridinium (MPP+).	Pramipexole	53-64	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	75-95
15473914-9	2004	MPTP- induced loss of striatal innervation, as measured by DAT-immunoreactivity, was partially prevented by pramipexole, but not with regard to TH-IR.	Pramipexole	108-119	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	59-62
15473914-10	2004	Pramipexole also reduced DAT- immunoreactivity in non-MPTP treated mice.	Pramipexole	0-11	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3	Mus musculus	25-28
15170083-4	2004	The neuroprotective effects of pramipexole seemed to be derived from several mechanisms: stimulation of D(2) autoreceptor, stimulation of D(3) receptor, inhibition of oxidative reaction and following radical production, increase of Bcl-2 protein and inhibition of apoptotic cell death, and production of neurotrophic factor.	Pramipexole	31-42	BCL2 apoptosis regulator	Homo sapiens	232-237
14655914-4	2003	PATIENTS: 60 consecutive patients treated with pramipexole for RLS.	Pramipexole	47-58	RLS1	Homo sapiens	63-66
14655914-6	2003	MEASUREMENTS AND RESULTS: Pramipexole was completely effective in controlling RLS in 67%, partially effective in 27%, and ineffective in 7% of patients.	Pramipexole	26-37	RLS1	Homo sapiens	78-81
14655914-14	2003	CONCLUSIONS: Pramipexole was effective for RLS with continued response with time.	Pramipexole	13-24	RLS1	Homo sapiens	43-46
10924701-0	2000	Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole.	Pramipexole	139-150	BCL2, apoptosis regulator	Rattus norvegicus	12-17
14521483-5	2003	Dopaminergic agents including levodopa and dopamine agonists such as pergolide, pramipexole, cabergoline and ropinirole are regarded as the treatment of choice for idiopathic RLS, however, the development of augmentation of symptoms, especially under levodopa therapy, may be a major problem.	Pramipexole	80-91	RLS1	Homo sapiens	175-178
12954356-0	2003	Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanisms.	Pramipexole	0-11	dopamine receptor D3	Mus musculus	46-66
12954356-2	2003	Pramipexole retained the ability to inhibit 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopamine depletion in mice in which the dopamine D3 receptor had been deleted.	Pramipexole	0-11	dopamine receptor D3	Mus musculus	144-164
12954356-4	2003	Furthermore, the dopamine D3 receptor selective antagonist 2-(3-[4-(2-tert-butyl-6-trifluoromethyl-4-pyrimidinyl)-1-piperazinyl]propylthio)-4-pyrimidinol (A-437203) partially inhibited the neuroprotective effect of pramipexole in dopamine D3 receptor expressing mice but not in receptor-deleted mice.	Pramipexole	215-226	dopamine receptor D3	Mus musculus	17-37
12482941-6	2002	At clinically relevant doses, pramipexole produced statistically robust decreases in rCBF in bilateral orbitofrontal cortex, thalamus, operculum, posterior and anterior (subgenual) cingulate cortex, and insula (in decreasing order of significance).	Pramipexole	30-41	CCAAT/enhancer binding protein zeta	Rattus norvegicus	85-89
12482941-8	2002	The dose-response curve and duration of pramipexole"s effects suggest that these rCBF responses indicate functional effects of a D3-preferring agonist.	Pramipexole	40-51	CCAAT/enhancer binding protein zeta	Rattus norvegicus	81-85
11419913-5	2001	However, the finding that pramipexole can normalise mitochondrial membrane potential and inhibit activity of caspase-3 in cytoplasmic hybrid cells derived from mitochondrial DNA of patients with nonfamilial Alzheimer"s disease suggests an even broader implication for the neuroprotective role of dopamine agonists.	Pramipexole	26-37	caspase 3	Homo sapiens	109-118
11261747-2	2001	In contrast to pergolide, a D1 and D2 dopamine agonist, pramipexole is a nonergoline dopamine agonist with D2 and preferential D3 dopamine receptor activity.	Pramipexole	56-67	dopamine receptor D3	Homo sapiens	127-147
12737528-3	2003	Recently, bromocriptine, pramipexole and several other agonists of the dopamine D2-receptor subfamily (including D2, D3 and D4-subtypes) have been shown to have neuroprotective effects in parkinsonian models in vitro and in vivo.	Pramipexole	25-36	dopamine receptor D2	Homo sapiens	71-91
12464116-5	2002	Pramipexole in particular has shown efficacy in reducing toxicity to MPTP, MPP, rotenone and 6-hydroxydopamine.	Pramipexole	0-11	M-phase phosphoprotein 6	Homo sapiens	75-78
11926889-0	2002	Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.	Pramipexole	60-71	solute carrier family 6 member 3	Homo sapiens	0-20
11402115-3	2001	METHODS: A randomized, assessor-blinded, placebo-controlled clinical trial was performed in subjects with early PD to determine whether L-dopa or pramipexole might regulate striatal DAT binding as measured by PET with [(11)C]RTI-32.	Pramipexole	146-157	solute carrier family 6 member 3	Homo sapiens	182-185
11402115-5	2001	RESULTS: Mean interval change in DAT binding was significantly reduced by 16% to 22% in all striatal regions (caudate, anterior and posterior putamen) of the L-dopa-treated patients, whereas significant changes in the pramipexole-treated patients were limited to the contralateral caudate (-15%), ipsilateral anterior putamen (-14%), and posterior putamen (-20%).	Pramipexole	218-229	solute carrier family 6 member 3	Homo sapiens	33-36
11402115-8	2001	CONCLUSIONS: Short-term therapy with L-dopa and, to a lesser extent, pramipexole can modestly down-regulate striatal DAT in patients with early PD.	Pramipexole	69-80	solute carrier family 6 member 3	Homo sapiens	117-120
11346069-1	2001	OBJECTIVE: To review the use of newer dopamine agonists pramipexole and ropinirole, in the treatment of restless legs syndrome (RLS).	Pramipexole	56-67	RLS1	Homo sapiens	128-131
11346069-4	2001	DATA SYNTHESIS: A number of small clinical studies of short duration have examined the use of pramipexole and ropinirole in the treatment of RLS.	Pramipexole	94-105	RLS1	Homo sapiens	141-144
11346069-7	2001	CONCLUSIONS: Although the published trials show promising results for efficacy of pramipexole and ropinirole in the treatment of RLS, they are subject to many limitations.	Pramipexole	82-93	RLS1	Homo sapiens	129-132
11301060-0	2001	Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole.	Pramipexole	120-131	cytochrome c, somatic	Homo sapiens	27-39
11301060-0	2001	Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole.	Pramipexole	120-131	synuclein alpha	Homo sapiens	44-59
11301060-2	2001	In the present study, we examined the effects of talipexole and pramipexole on the release of cytochrome c and alpha-synuclein, their aggregations, and activation of caspases.	Pramipexole	64-75	cytochrome c, somatic	Homo sapiens	94-106
11301060-2	2001	In the present study, we examined the effects of talipexole and pramipexole on the release of cytochrome c and alpha-synuclein, their aggregations, and activation of caspases.	Pramipexole	64-75	synuclein alpha	Homo sapiens	111-126
11301060-4	2001	Talipexole and pramipexole at low concentration (0.1-1 mM) significantly inhibited the accumulation of cytochrome c or alpha-synuclein in the cytosolic fraction.	Pramipexole	15-26	cytochrome c, somatic	Homo sapiens	103-115
11301060-4	2001	Talipexole and pramipexole at low concentration (0.1-1 mM) significantly inhibited the accumulation of cytochrome c or alpha-synuclein in the cytosolic fraction.	Pramipexole	15-26	synuclein alpha	Homo sapiens	119-134
11301060-7	2001	These results suggest that talipexole and pramipexole may have protective effects against the neurodegeneration, which is induced by intracellular accumulation of cytochrome c and alpha-synuclein.	Pramipexole	42-53	cytochrome c, somatic	Homo sapiens	163-175
11301060-7	2001	These results suggest that talipexole and pramipexole may have protective effects against the neurodegeneration, which is induced by intracellular accumulation of cytochrome c and alpha-synuclein.	Pramipexole	42-53	synuclein alpha	Homo sapiens	180-195
10924701-1	2000	Treatment of rats for 4 days with the antiparkinsonian drugs, talipexole and pramipexole, markedly increased Bcl-2 immunoreactivity in neuronal dendritic processes in both cerebral cortex and hippocampus, but treatment for 1 day with either of these drugs did not.	Pramipexole	77-88	BCL2, apoptosis regulator	Rattus norvegicus	109-114
7814630-4	1995	Western blot analysis revealed that in renal cortical membranes, fenoldopam and pramipexole increased expression of PLC beta 1 and decreased expression of PLC gamma 1; PLC delta was unchanged.	Pramipexole	80-91	phospholipase C beta 1	Rattus norvegicus	116-126
11054154-7	2000	Pramipexole is a full dopamine agonist with high selectivity for the D2 dopamine receptor family.	Pramipexole	0-11	dopamine receptor D2	Homo sapiens	69-89
11054154-9	2000	Pramipexole has a 5- to 7-fold greater affinity for the D3 receptor subtype with lower affinities for the D2 and D4 receptor subtypes.	Pramipexole	0-11	dopamine receptor D4	Homo sapiens	113-124
10812530-1	2000	Pramipexole, a dopamine D2 receptor agonist, was tested in 174 patients with major depression, with or without melancholia and without psychotic features.	Pramipexole	0-11	dopamine receptor D2	Homo sapiens	15-35
10201413-1	1999	OBJECTIVES: Pramipexole, a non-ergot dopamine D2/D3 receptor agonist, was investigated as an add on drug in advanced parkinsonian patients with motor fluctuations to assess efficacy, safety, and tolerance.	Pramipexole	12-23	dopamine receptor D2	Homo sapiens	37-60
10234741-0	1999	[3H]Pramipexole: a selective radioligand for the high affinity dopamine D2 receptor in bovine striatal membranes.	Pramipexole	4-15	dopamine receptor D2	Bos taurus	63-83
9855633-7	1998	Similarly, pramipexole pretreatment increased Bcl-2 and inhibited MPP+-induced apoptosis.	Pramipexole	11-22	BCL2 apoptosis regulator	Homo sapiens	46-51
8665547-1	1995	We evaluated the efficacy, safety, tolerability, and pharmacokinetics of pramipexole, a novel dopamine D2 receptor agonist, in early Parkinson"s disease (PD).	Pramipexole	73-84	dopamine receptor D2	Homo sapiens	94-114
7814630-4	1995	Western blot analysis revealed that in renal cortical membranes, fenoldopam and pramipexole increased expression of PLC beta 1 and decreased expression of PLC gamma 1; PLC delta was unchanged.	Pramipexole	80-91	phospholipase C, gamma 1	Rattus norvegicus	155-166
7814630-5	1995	In the cytosol, pramipexole and fenoldopam increased expression of both PLC beta 1 and PLC gamma 1.	Pramipexole	16-27	phospholipase C beta 1	Rattus norvegicus	72-82
7814630-5	1995	In the cytosol, pramipexole and fenoldopam increased expression of both PLC beta 1 and PLC gamma 1.	Pramipexole	16-27	phospholipase C, gamma 1	Rattus norvegicus	87-98
8748629-1	1995	We evaluated the efficacy, safety and tolerability of a new dopamine D-2 receptor agonist, pramipexole [(S)-2-amino-4,5,6,7-tetrahydro-6-propylamino-benzathiazol-dihydro chloride], as adjunctive therapy in patients with advanced Parkinson"s disease (PD).	Pramipexole	91-102	dopamine receptor D2	Homo sapiens	60-81
34218945-9	2022	CONCLUSIONS: Pramipexole improved behavior of PD model rat, and down regulated the mRNA expression and concentrations of IL-6 and TNF-alpha in their CNS.	Pramipexole	13-24	interleukin 6	Rattus norvegicus	121-125
2142088-2	1990	The basal serum prolactin levels were reduced dose dependently by s.c. administration of talipexole or SND 919 at doses of 5-100 micrograms/kg.	Pramipexole	103-110	prolactin	Rattus norvegicus	16-25
2142088-5	1990	In vitro, the spontaneous prolactin release into perfusates from isolated anterior pituitary was inhibited by talipexole or SND 919 added at concentrations ranging from 10(-9) to 10(-6) M. This inhibitory effect of SND 919 was blocked by concurrent application of a dopamine D-2 receptor antagonist, YM-09151-2.	Pramipexole	124-131	prolactin	Rattus norvegicus	26-35
2142088-5	1990	In vitro, the spontaneous prolactin release into perfusates from isolated anterior pituitary was inhibited by talipexole or SND 919 added at concentrations ranging from 10(-9) to 10(-6) M. This inhibitory effect of SND 919 was blocked by concurrent application of a dopamine D-2 receptor antagonist, YM-09151-2.	Pramipexole	215-222	prolactin	Rattus norvegicus	26-35
2142088-9	1990	The results suggest that talipexole and SND 919 have a selective dopamine D-2 receptor agonistic property and are almost completely effective to counteract the enhancement of prolactin release induced by estrogens via stimulation of dopamine D-2 receptors in the anterior pituitary.	Pramipexole	40-47	prolactin	Rattus norvegicus	175-184
1357983-2	1992	Because dopamine has actions on receptors (e.g., adrenergic, serotonin) other than dopamine, we studied a novel dopamine agonist, pramipexole, which has a selectivity to both DA1 and DA2-receptor subtypes.	Pramipexole	130-141	RT1 class II, locus Da	Rattus norvegicus	175-178
1357983-5	1992	The renal effects of pramipexole were mainly due to actions at the DA1 receptor, since these effects were completely blocked by the coinfusion of a DA1 antagonist, SKF 83742.	Pramipexole	21-32	RT1 class II, locus Da	Rattus norvegicus	67-70
1357983-5	1992	The renal effects of pramipexole were mainly due to actions at the DA1 receptor, since these effects were completely blocked by the coinfusion of a DA1 antagonist, SKF 83742.	Pramipexole	21-32	RT1 class II, locus Da	Rattus norvegicus	148-151
1350237-3	1992	Pramipexole decreased serum prolactin levels in a dose-dependent manner, with a maximum effect after 2 to 4 hours.	Pramipexole	0-11	prolactin	Homo sapiens	28-37
34218945-9	2022	CONCLUSIONS: Pramipexole improved behavior of PD model rat, and down regulated the mRNA expression and concentrations of IL-6 and TNF-alpha in their CNS.	Pramipexole	13-24	tumor necrosis factor	Rattus norvegicus	130-139
34810175-3	2022	Previous small randomised controlled trials suggested that pramipexole, a dopamine D2/3 receptor agonist, may be effective for treating patients with unipolar and bipolar depression as it is known to influence motivational drive and reward processing.	Pramipexole	59-70	dopamine receptor D2	Homo sapiens	74-96
34699917-0	2021	Pramipexole Regulates Depression-Like Behavior via Dopamine D3 Receptor in a Mouse Model of Parkinson"s Disease.	Pramipexole	0-11	dopamine receptor D3	Mus musculus	51-71
34699917-7	2021	Pramipexole significantly improved depression-like behavior in DRD2-/- mice but not in DRD3-/- mice.	Pramipexole	0-11	dopamine receptor D2	Mus musculus	63-67
34699917-8	2021	These results demonstrate that the antidepressive effect of pramipexole is mediated by DRD3 but not DRD2.	Pramipexole	60-71	dopamine receptor D3	Mus musculus	87-91
34451897-1	2021	Treatment with the dopamine D2/D3 receptor agonist pramipexole has demonstrated promising clinical effects in patients with depression.	Pramipexole	51-62	dopamine receptor D2	Homo sapiens	19-42
34432265-10	2021	We observed that PPX treatment downregulated IL-1beta levels and increased BNDF content in the spinal cord after EAE induction.	Pramipexole	17-20	interleukin 1 alpha	Mus musculus	45-53
34708087-7	2021	In response to scratch injury, WT cardiac fibroblasts treated with the D3R agonist, pramipexole, displayed enhanced migration compared to control WT and D3KO cells.	Pramipexole	84-95	dopamine receptor D3	Mus musculus	71-74
35605609-0	2022	Enhanced taste recognition following subacute treatment with the dopamine D2/D3 receptor agonist pramipexole in healthy volunteers.	Pramipexole	97-108	dopamine receptor D2	Homo sapiens	65-88
34249258-0	2021	Dopaminergic agonist pramipexole improves memory and increases IL-10 production in LPS-challenged rats.	Pramipexole	21-32	interleukin 10	Rattus norvegicus	63-68
34249258-12	2021	Interleukin (IL)-10 serum levels were elevated by 1 mg/kg PMX.	Pramipexole	58-61	interleukin 10	Rattus norvegicus	0-19
34249258-14	2021	PMX at all doses significantly decreased BDNF serum concentration.	Pramipexole	0-3	brain-derived neurotrophic factor	Rattus norvegicus	41-45
35609673-3	2022	RLS can generally be well treated with medications such as alpha-2-delta calcium channel ligands (A2Ds) gabapentin, pregabalin, gabapentin enacarbil or, if these are poorly tolerated or lack efficacy, dopamine agonists (DAs), pramipexole, ropinirole or rotigotine.	Pramipexole	226-237	RLS1	Homo sapiens	0-3
33493581-0	2021	Pramipexole attenuates neuronal injury in Parkinson"s disease by targeting miR-96 to activate BNIP3-mediated mitophagy.	Pramipexole	0-11	microRNA 96	Mus musculus	75-81
35524855-7	2022	After treatment with Pramipexole, the neurofunctional deficits, behavioral disability, and aggravated pathological changes were dramatically reversed, accompanied by the alleviated BBB permeability, and upregulated occludin, an important tight junction protein.	Pramipexole	21-32	occludin	Mus musculus	215-223
35524855-10	2022	Increased fluorescence intensity of FITC-dextran, reduced value of TEER, and downregulated occludin and KLF2 were observed in TBI-exposed cells, all of which were greatly reversed by 10 and 20 muM Pramipexole.	Pramipexole	197-208	occludin	Mus musculus	91-99
35524855-10	2022	Increased fluorescence intensity of FITC-dextran, reduced value of TEER, and downregulated occludin and KLF2 were observed in TBI-exposed cells, all of which were greatly reversed by 10 and 20 muM Pramipexole.	Pramipexole	197-208	Kruppel-like factor 2 (lung)	Mus musculus	104-108
35524855-11	2022	Furthermore, in KLF2-silenced bEnd.3 cells, the protective ability of Pramipexole against endothelial permeability and the expression level of occludin were dramatically abolished.	Pramipexole	70-81	Kruppel-like factor 2 (lung)	Mus musculus	16-20
35524855-11	2022	Furthermore, in KLF2-silenced bEnd.3 cells, the protective ability of Pramipexole against endothelial permeability and the expression level of occludin were dramatically abolished.	Pramipexole	70-81	occludin	Mus musculus	143-151
35524855-12	2022	Collectively, our results suggest that Pramipexole protected against TBI-induced BBB dysfunction by mediating KLF2.	Pramipexole	39-50	Kruppel-like factor 2 (lung)	Mus musculus	110-114
35463692-3	2022	Compared with that in normal group, the positive expression of BDNF was substantially increased in model group and pramipexole group, and its positive expression in pramipexole group was notably higher than that in model group.	Pramipexole	115-126	brain-derived neurotrophic factor	Rattus norvegicus	63-67
35463692-3	2022	Compared with that in normal group, the positive expression of BDNF was substantially increased in model group and pramipexole group, and its positive expression in pramipexole group was notably higher than that in model group.	Pramipexole	165-176	brain-derived neurotrophic factor	Rattus norvegicus	63-67
35463692-5	2022	The relative expression levels of miR-103a and miR-30b in model and pramipexole groups were markedly higher than those in normal group, and pramipexole group had remarkably higher relative expression levels of miR-103a and miR-30b than model group.	Pramipexole	68-79	microRNA 30b	Rattus norvegicus	47-54
35463692-5	2022	The relative expression levels of miR-103a and miR-30b in model and pramipexole groups were markedly higher than those in normal group, and pramipexole group had remarkably higher relative expression levels of miR-103a and miR-30b than model group.	Pramipexole	68-79	microRNA 30b	Rattus norvegicus	223-230
35463692-5	2022	The relative expression levels of miR-103a and miR-30b in model and pramipexole groups were markedly higher than those in normal group, and pramipexole group had remarkably higher relative expression levels of miR-103a and miR-30b than model group.	Pramipexole	140-151	microRNA 30b	Rattus norvegicus	47-54
35463692-5	2022	The relative expression levels of miR-103a and miR-30b in model and pramipexole groups were markedly higher than those in normal group, and pramipexole group had remarkably higher relative expression levels of miR-103a and miR-30b than model group.	Pramipexole	140-151	microRNA 30b	Rattus norvegicus	223-230
35463692-6	2022	It was found through ELISA that model and pramipexole groups had markedly raised IL-1beta and IL-18 content compared with normal group, and their content in pramipexole group was remarkably lower than that in model group.	Pramipexole	42-53	interleukin 1 alpha	Rattus norvegicus	81-89
35463692-6	2022	It was found through ELISA that model and pramipexole groups had markedly raised IL-1beta and IL-18 content compared with normal group, and their content in pramipexole group was remarkably lower than that in model group.	Pramipexole	42-53	interleukin 18	Rattus norvegicus	94-99
35463692-8	2022	Pramipexole may up-regulate the expressions of BDNF, miR-103a and miR-30b to inhibit the apoptosis and inflammation in Parkinson"s disease model rats.	Pramipexole	0-11	brain-derived neurotrophic factor	Rattus norvegicus	47-51
35463692-8	2022	Pramipexole may up-regulate the expressions of BDNF, miR-103a and miR-30b to inhibit the apoptosis and inflammation in Parkinson"s disease model rats.	Pramipexole	0-11	microRNA 30b	Rattus norvegicus	66-73
33493581-11	2021	miR-96 overexpression or BNIP3 interference weakened the suppressive role of PPX in MPP+-induced neuronal injury.	Pramipexole	77-80	microRNA 96	Mus musculus	0-6
33493581-11	2021	miR-96 overexpression or BNIP3 interference weakened the suppressive role of PPX in MPP+-induced neuronal injury.	Pramipexole	77-80	BCL2/adenovirus E1B interacting protein 3	Mus musculus	25-30
33493581-15	2021	CONCLUSION: PPX mitigated neuronal injury in MPP+-induced cells and MPTP-induced mice by activating BNIP3-mediated mitophagy via directly decreasing miR-96.	Pramipexole	12-15	BCL2/adenovirus E1B interacting protein 3	Mus musculus	100-105
33493581-15	2021	CONCLUSION: PPX mitigated neuronal injury in MPP+-induced cells and MPTP-induced mice by activating BNIP3-mediated mitophagy via directly decreasing miR-96.	Pramipexole	12-15	microRNA 96	Mus musculus	149-155
34269222-0	2022	Pramipexole, a dopamine D3/D2 receptor-preferring agonist, attenuates reserpine-induced fibromyalgia-like model in mice.	Pramipexole	0-11	dopamine receptor D3	Mus musculus	15-38
34269222-4	2022	Our results showed that pramipexole (PPX) - a dopaminergic D3/D2 receptor agonist - inhibited mechanical allodynia and thermal sensitivity induced by reserpine.	Pramipexole	24-35	dopamine receptor D2	Mus musculus	59-73
34269222-4	2022	Our results showed that pramipexole (PPX) - a dopaminergic D3/D2 receptor agonist - inhibited mechanical allodynia and thermal sensitivity induced by reserpine.	Pramipexole	37-40	dopamine receptor D2	Mus musculus	59-73
33493581-0	2021	Pramipexole attenuates neuronal injury in Parkinson"s disease by targeting miR-96 to activate BNIP3-mediated mitophagy.	Pramipexole	0-11	BCL2/adenovirus E1B interacting protein 3	Mus musculus	94-99
33264473-8	2021	The DRD2 agonist, pramipexole, administered systemically caused colorectal propulsion that was prevented when the pelvic nerves were cut.	Pramipexole	18-29	dopamine receptor D2	Homo sapiens	4-8
33891271-0	2021	Pramipexole attenuates 6-OHDA-induced Parkinson"s disease by mediating the Nurr1/NF-kappaB pathway.	Pramipexole	0-11	nuclear receptor subfamily 4, group A, member 2	Rattus norvegicus	75-80
33891271-14	2021	PPX improved the motor behavior of PD through mediating the inflammatory response and regulating the Nurr1/NF-kappaB signaling pathway.	Pramipexole	0-3	nuclear receptor subfamily 4, group A, member 2	Rattus norvegicus	101-106